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Formation of functional collateral circulation, to repair blocked or damaged arterial 
blood flow, is an important process in amending adverse outcomes after acute coronary 
occlusion events. Inadequate capillary growth during pressure overloads impairs myocardial 
perfusion, often contributing to the progression of coronary heart disease and ischaemia.  
Considered to be the critical rate-limiting step in physiological angiogenesis, the binding of 
VEGF (vascular endothelial growth factor) to VEGFR (vascular endothelial growth factor 
receptors) is essential for the growth and repair of arteries. Conversely, VEGF mediated 
angiogenesis has also been shown to promote atherosclerosis through arterial wall thickening. 
However, an alternatively spliced soluble form of VEGFR-1 (sFlt-1) has been shown to inhibit 
VEGF activity. sFlt-1 binds and sequesters free extracellular VEGF and/or heterodimerizes 
with VEGFR preventing the angiogenic pathway occurring. As a result, the primary pathway 
of angiogenesis does not occur. In recent years this has led to debate over the nature of sFlt-1 
in the VEGF system. However, the level of sFlt-1 found in cardiovascular disease (CVD) 
patients, as well as its stability in plasma, has allowed for current research into its involvement 
with ischemic disorders to take place.   
 
Enhanced T-cell activity that results in increased production of interferon-γ has been 
shown to have involvement in the pathogenesis of CVD. 7,8-dihydroneopterin (7,8 NP) 
production by monocytes and macrophages is primarily in response to stimulation by 
interferon-γ (IFN-γ) released by activated T-lymphocytes. When combined with neopterin, the 
oxidised product of 7,8 NP, the total neopterin is accounted for which is a measure of the total 
macrophage activation by interferon-γ. Therefore, the levels of total neopterin observed may 
reflect the level of cell-mediated immunity within individuals which could contribute to 
mortality post CVD event. 
 
  Progression of coronary heart disease is often clinically silent, without signs or 
symptoms. For this reason, the ability of markers to monitor progression is a powerful tool for 
predicting cardiovascular risk and the level of preventative treatment required. This study 
shows, that in 514 stable post-ACS (MI or unstable angina) patients, above median baseline 
sFlt-1, total neopterin and 7,8 NP levels, were strong predictors of mortality over a median 5 
year period. Furthermore, above median sFlt-1 levels were specifically predictive of CVD 
death (p=0.001). This suggests that sFlt-1, total neopterin and 7,8 NP may be useful markers 
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for risk prediction in CVD patients, post-acute event, with potential to aid prognosis in 
previously diagnosed patients. 
 
 In support of these findings, levels of sFlt-1 measured in plasma taken from patients, 
immediately prior to undergoing carotid endarterectomy procedures (n=27), were significantly 
raised in comparison to age and gender matched healthy controls (p<0.001). Furthermore, 
levels of sFlt-1 in patient and control groups were shown to be independent of both age and 
gender. 
 
 Another aspect of the study, analysis of excised live plaque tissue from carotid 
endarterectomy patients, showed the presence of live inflammatory cell populations. 
Macrophages, in the plaque sections, could be stimulated in the presence of IFN-γ to produce 
significantly elevated (p<0.01) levels of the antioxidant 7,8 NP. Since bivariate analysis of 7,8 
NP and sFlt-1, in plasma from the endarterectomy patients, yields a positive correlation 
(r=0.323, p<0.01), further analysis of live plaque may give insight into the association between 
inflammation and hypoxic up-regulation of sFlt-1.   
 
 It is now generally accepted, in diseases with complex pathogenesis, that particular 
biomarkers are predominantly indicative of only a single variable in a wide range of 
contributing factors. The data generated in this study highlights the potential for sFlt-1, 
neopterin and 7,8 NP to be used as contributing biomarkers in the prognosis of patients 
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1.1 Atherosclerotic plaque progression  
 
Pathophysiology of Cardiovascular disease  
 Major advances in understanding the underlying pathophysiology behind 
atherosclerosis have been achieved over the last 30 years. Previously considered a lipid storage 
disease, atherosclerosis, thought to be the leading cause of coronary artery disease, is now 
viewed as an inflammatory disorder (Siegel et al., 2013).   
 
 Acute myocardial ischaemia, like other manifested disorders of cardiovascular and 
cerebrovascular disease such as unstable angina and strokes, usually occurs following 
development of a fibrolipid plaque. However, the initial mechanism of atheroma development, 
prior to formation of an arterial fatty streak, is still under debate over three main hypotheses 
(Stocker & Keaney Jr, 2004). 
 
 The “response to injury hypothesis” first proposed in 1977 by Ross and Glomset, 
contradicted prior hypotheses of passive lipid and fibrin deposition, suggesting instead that 
prolonged damage to the arterial endothelium may be responsible. This repeated or chronic 
injury of the endothelium is said to upset the vascular homeostatic balance, resulting in distinct 
sites of smooth muscle proliferation and sequestering of lipid at the site of injury (Ross, 
Glomset, & Harker, 1977) (Fig. 1). 
Fig 1. The response to injury hypothesis (Ross et al., 1977). A: Increased endothelial 
permeability occurs as a result of prolonged damage to the arterial endothelium resulting in 
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LDL accumulation in the sub-endothelial space. This promotes the adhesion and migration of 
inflammatory cells into the sub-endothelial space. B: Foam cell formation occurs following 
macrophage uptake of modified LDL in the sub-endothelial space. T-cell activation further 
promotes the migration of inflammatory cells to the sub-endothelial space advancing the 
atherosclerotic plaque formation. C: A fully formed fibro-lipid plaque. Characterised by 
continued macrophage accumulation, a necrotic core and a fibrous cap (Stocker & Keaney Jr, 
2004).  
 
The “oxidative modification hypothesis” was originally proposed on the basis of two 
different experiments. Firstly that injury to cells by LDL was dependent upon its oxidation 
(Hessler, Morel, Lewis, & Chisolm, 1983; Morel & Chisolm, 1984; Morel, Hessler, & Chisolm, 
1983) and secondly that cultured cells could modify native LDL in media, to a form recognized 
by scavenger receptors on macrophages, which was shown to be a result of oxidative 
modification (Henriksen, Mahoney, & Steinberg, 1981, 1983) (Fig. 2). 
 
Fig. 2 The oxidative modification hypothesis (Henriksen et al., 1981, 1983; Hessler et al., 
1983; Morel & Chisolm, 1984; Morel et al., 1983). A: Circulating LDL accumulates in the sub-
endothelial space where it is subject to oxidative modification. B&C: This oxidised LDL 
stimulates monocyte chemotaxis eventually causing foam cell formation as it is engulfed by 
macrophages. D: Oxidised LDL also results in endothelial dysfunction contributing to the 
necrotic core (Epstein, Diaz, Frei, Vita, & Keaney Jr, 1997). 
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Lastly the “response to retention hypothesis” suggests that arterial lipoprotein retention 
is the defining event in atherosclerotic initiation (Williams & Tabas, 1995). Hyperlipidemia is 
said to cause lesion development at specific points in the artery, which express apolipoprotein 
B (ApoB) retentive molecules. Therefore ApoB containing lipoproteins are somewhat 
restricted at these points, where they may encroach on the sub-endothelial tissue via 
transcytosis (Proctor, Vine, & Mamo, 2002). This accumulated lipoprotein may then prompt a 
chemotaxic event, triggering an inflammatory response, which results in the recruitment of 
monocytes and other inflammatory cells to the arterial intima (Fig. 3). 
 
Fig 3. The response to retention hypothesis (Williams & Tabas, 1995). Apolipoprotein B 
(Apo-B) retentive molecules within the artery lead to accumulation and aggregation of LDL 
(1-5). Accumulation of the apolipoprotein B containing lipoproteins is then thought to further 
promote pro-inflammatory cascades in the sub-endothelial space (Stocker & Keaney Jr, 2004).  
 
Though all three hypotheses have merit, lipoprotein retention, oxidative damage and 
chronic inflammation are all intimately related to the early progression of atherosclerotic 
plaques. Therefore, atherosclerotic initiation is now more commonly noted as a unified model 
of these three concepts (Fuster, Moreno, Fayad, Corti, & Badimon, 2005).        
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Although there is still debate over the initial stages of plaque formation, it is now well 
documented that the inflammatory response comes as a result of lipid filled inflammatory cells 
(mainly macrophages) and T-cells within the arterial wall. These cells, more often than not, are 
highly activated producing pro-coagulant and inflammatory mediators such as tumour necrosis 
factor-α (TNF-α) and IFN-γ. This inflammatory cell accumulation and subsequent death leads 
to asymmetrical focal thickening of the arterial intima, forming what is known as an 
atherosclerotic plaque (Hegyi, Skepper, Cary, & Mitchinson, 1996).  
 
If growth of the plaque is unrelieved, destabilization can occur resulting in plaque 
rupture and release of highly thrombogenic materials such as tissue factor, fragments of 
collagen and crystalline surfaces which accelerate the process of blood coagulation (Davies, 
2000). The two mechanisms by which the plaque may rupture (tearing of the fibrous cap or 
breakdown of the fibrous cap by proteases released by macrophages) are both a reflection of 
the enhanced inflammatory activity within the plaque (Davies, 2000). When exposed to the 
artery lumen blood coagulation and thrombogenic factors cause aggregation of activated 
platelets, which occlude the artery, restricting blood flow and reducing the efficiency of oxygen 
transport. Furthermore, whilst blood flows past the occluding thrombus, activated platelets are 
swept into distal arteries which may result in the formation of emboli and further artery 
occlusion (Libby, 2001) (Fig. 4)  
Fig 4. Progression of atherosclerosis. A: LDL enters the arterial intima, where it is modified 
by oxidation or enzymatic activity and aggregates within the sub-endothelial space, this 
promotes its uptake by macrophages. Unregulated uptake of lipoproteins by macrophages leads 
to the generation of foam cells. The accumulation of foam cells leads to the formation of fatty 
streaks. B: Vascular smooth muscles contribute to the inflammatory process via cytokine 
driven recruitment of further inflammatory cells to the arterial intima. As the plaque grows 
compensatory remodelling takes place, narrowing the arterial lumen diameter, which restricts 
blood flow and increases blood pressure. C: Foam cells eventually die resulting in the release 
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of cellular debris and crystalline cholesterol. As well as contributing to the necrotic core, this 
process results in further macrophage recruitment. This advanced plaque is prone to rupture 
releasing thrombogenic material, including tissue factor, resulting in the formation of a 
thrombus in the artery lumen. If the thrombus is large enough it can block the artery preventing 
downstream oxygen supply, ultimately resulting in clinically observable manifestations, such 
as myocardial infarction (MI). D: Alternatively, the plaque may not rupture but continue to 
grow. This results in a silently occlusive process which often manifests as angina (Rader & 
Daugherty, 2008).  
 
A loss of oxygen perfusion to the myocardial tissue, as a result of thrombus formation, 
may result in clinical manfestations of CVD such as MI. Likewise the loss of blood flow in 
arteries which perfuse the brain causing strokes is another manifestation of atherosclerosis. 
However, this is often referred to as cerebrovascular disease. In order to simplify the pathology 
of these two clinical syndromes, coronary artery disease and cerebrovascular disease are 
referred to collectively as CVD (Stocker & Keaney Jr, 2004). 
 
Epidemiology/ of CVD in relation to heart failure and stroke  
 In New Zealand alone, CVD, characterized mostly by clinical manifestation events such 
as strokes, MI, unstable angina and heart failure, is second only to all forms of cancer, in the 
rate of mortality caused by disease (Hay, 2002). Furthermore, recent studies have indicated that 
approximately 25% of patients who are discharged following treatment of a CVD event are re-
admitted within one year (Ross et al., 2009; Selim, Velankar, Soghier, & Zolty, 2011). For this 
reason research into the development of diagnostic tools for the early detection and prognosis 
in CVD patients has been of great interest. 
 
 Challenges in the diagnosis of CVD, and an increased prevalence with advancing age 
(Gross, Chaudhry, Leo-Summers, & Fried, 2011), often makes intervention prior to a CVD 
event difficult. With the notion that abnormal ischemic events play a detrimental role in the 
development of CVD; mediators of vascular function and their receptors may provide valuable 
prognostic information as biomarkers of the disease.  
 
In accordance with various health statistics, repeated ischemic events in the 
myocardium, characterized by an inadequate supply of oxygen-rich blood to the heart muscles, 
is generally associated with CVD. This suggests that recurrent ischemic events may be one of 
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the dominant mechanisms leading to exacerbation of and progression of heart failure (Khand, 
Gemmell, Rankin, & Cleland, 2001).  
 
Recent heart disease and stroke statistics highlight the importance of accurate diagnosis 
and reliable prognostic markers of cardiovascular disease. According to the most recent 
summary by the American Heart Association, CVD events still account for one in every three 
of all the 2,437,163 deaths per year in the USA, with 1 in every 6 and 1 in every 19 from 
coronary artery disease and strokes, respectively. Overall, CVD accumulates a cost of 
approximately US$312.6 billion annually to the US economy, further highlighting the need to 
identify early signs of the disease so adequate preventative measures can be taken such as 
cessation of smoking and monitoring of dietary and exercise habits (Go et al., 2013). 
 
1.2 VEGF and its receptors in CVD  
 
The vascular endothelial growth factor (VEGF) pathway  
 New blood vessel growth and repair is a highly complex process, thought to require 
sequential activation via a series of ligands and their corresponding receptors. However, VEGF 
signalling is known as the critical rate limiting step in physiological angiogenesis (Ferrara, 
Gerber, & LeCouter, 2003).  
 
VEGF-A is one of five related growth factors, including VEGF-B, VEGF-C, VEGF-D 
and placenta growth factor (PlGF), which bind primarily to three tyrosine kinase receptors with 
differing affinity. In addition to these five factors, a series of VEGF-A splice variants may bind 
to corresponding VEGF receptors, but fail to evoke any response and have therefore been 
described as anti-angiogenic (Harper & Bates, 2008).   
 
The structurally related VEGF receptors, denoted VEGFR1/FMS-like tyrosine kinase-
1 (Flt-1), VEGFR2/Kinase insert domain receptor (KDR) and VEGFR3 (Flt-4) have an 
overlapping, but distinct expression pattern, with Flt-1 in monocytes, macrophages and 
vascular endothelial cells, KDR in vascular endothelial cells and Flt-4 in lymphatic endothelial 
cells (Koch & Claesson-Welsh, 2012). However, the complexity of these receptors is increased 




Hypoxic tension, in such circumstances as stenosis caused by CVD, mediates the 
regulation and expression of several VEGF family ligands and receptors via Hypoxia inducible 
factor-1 (HIF-1) (Banai et al., 1994; Germain, Monnot, Muller, & Eichmann, 2010; Vissers, 
Gunningham, Morrison, Dachs, & Currie, 2007). This up-regulation in hypoxic conditions 
leads to increased expression in states of growth (embryonic development) and disease (cancer 
and CVD).  
 
Flt-1, the first receptor tyrosine kinase to be identified as a VEGF receptor, is also up-
regulated by hypoxia in a HIF-1-dependent mechanism (Sandner, Wolf, Bergmaier, Gess, & 
Kurtz, 1997). Although Flt-1 binds VEGFA, VEGFB and PIGF its kinase activity is poor 
(Eichmann & Simons, 2012; Koch & Claesson-Welsh, 2012). It has therefore been 
hypothesised that Flt-1 is not required as an endothelial signalling receptor, but may instead 
serve to capture VEGFA in order to mediate formation of angiogenic sprouts through KDR 
(Kappas et al., 2008). In support of this, mouse models with deletion of the Flt-1 tyrosine kinase 
domain are compatible with vascular development (Hiratsuka et al., 2001). However, this is 




Although the exact function of Flt-1 is still under debate, it is well known and 
documented that binding of VEGF-A to KDR promotes the growth of vascular endothelial 
cells, prompting a potent angiogenic response to hypoxic conditions. This results in the 
remodelling of arteries, production of new blood vessels and vasodilatation (Ku, Zaleski, Liu, 
& Brock, 1993) to relieve stress caused by disorders such as CVD (Schaper & Buschmann, 
Fig 5. VEGF receptors and the 
corresponding angiogenic 
machinery. Binding of vascular 
growth factors to KDR is shown to 
elicit pathways necessary for 
angiogenic up regulation.(Kerbel, 
2008)   
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1999). Furthermore, mouse model studies have shown that KDR knockout is not compatible 
with vascular development (Cai, Jiang, Ahmed, & Boulton, 2006). 
 
 Soluble Flt-1 (sFlt-1) is an alternatively spliced circulating form of Flt-1 with equal 
affinity for VEGF. However, in contrast to Flt-1, sFlt-1 is produced mainly by endothelial cells 
and deposited in their extracellular matrix (Orecchia et al., 2003). 
 
 Acting as a decoy, sFlt-1 (also up-regulated by hypoxia) binds VEGF in the blood, 
inhibiting the angiogenic action which occurs from VEGF binding to membrane bound KDR 
on endothelial cells in the artery (Belgore, Blann, & Lip, 2001). Consequently it has been 
implicated as a negative regulator of angiogenesis (Fig. 6). It is therefore not surprising that 
elevated levels of sFlt-1, following acute myocardial ischemia in CVD patients, have been 
associated with increased risk of future CVD events as neovascularization is hindered 
(Hochholzer et al., 2011; Kapur et al., 2011; Kim et al., 2011). However, contrary to this, gene 
delivery of sFlt-1 has been shown to inhibit intra-plaque angiogenesis which supresses 
atherosclerotic plaque development (Wang et al., 2011). 
 
   
Despite these contrary findings in varying diseases, where a balance of anti- angiogenic 
and angiogenic factors play a key role in the context of their pathology, such as MI (Searle et 
al., 2012) and pre-eclampsia (Seki, 2014), s-Flt-1 has been shown to be a valuable diagnostic 
and prognostic marker. In support of its potential utility patients referred for emergent 
percutaneous coronary revascularization and active chest pain, with acute coronary occlusion, 
exhibited significantly elevated sFlt-1 serum levels (Kapur et al., 2011). 
 
 
Fig 6. Regulation of VEGF 
signalling. Strict regulation of 
VEGF signalling occurs through 
sFlt-1.  sFlt-1 binds and 
sequesters VEGF from cell-
surface VEGF receptors, 
subsequently the 
VEGF modulated pro-angiogenic 
signal is inhibited (L. Xu, 




Utility of sFlt-1as a prognostic marker of CVD 
 An imbalance of anti-angiogenic and angiogenic factors, causing abnormal vascular 
growth, plays a major role in the progression of CVD (Lip & Chung, 2005). Alteration in 
angiogenic growth factors (such as VEGF) results in endothelial cell dysfunction and a lack of 
vascularization, also causing an increase in pressure and afterload putting strain on the heart 
(Carmeliet, 2005). It has been shown, and is now well documented, that Flt-1 as well as sFlt-1 
are upregulated during ischemia (Gerber, Condorelli, Park, & Ferrara, 1997; Koch & Claesson-
Welsh, 2012).  
 
 Since levels of sFlt-1 are associated with inhibition of VEGF activity, there have been 
studies into sFlt-1’s potential for biomarker use in CVD (Searle et al., 2012). However, not all 
studies have provided the same results. Recent reports have shown that plasma levels of sFlt-1 
are associated with increased disease severity in chronic CVD (Kim et al., 2011; Ky et al., 
2011). Furthermore, other work has shown the prognostic utility of sFlt-1 in predicting the 
clinical outcome of post-percutaneous coronary intervention MI patients (Searle et al., 2012). 
On the other hand, data obtained by Kodama et al. indicates that plasma sFlt-1 is lower in 
patients with acute MI (Kodama et al., 2006). These contradictory findings are difficult to 
explain. However, there is an overwhelming body of data in support of sFlt-1’s association 
with CVD events (Hochholzer et al., 2011; Kapur et al., 2011; Onoue et al., 2009). 
Furthermore, past evidence also indicates that levels of Flt-1, as well as sFlt-1 are significantly 
increased in the acute phase of myocardial ischemia (Kapur et al., 2011; Xu et al., 2001). 
 
Since HIF-1 binding in the Flt-1 promoter region is responsible for the hypoxia induced 
up-regulation of Flt-1, sFlt-1 mRNA is also up-regulated under hypoxic conditions. This has 
led to the general consensus that sFlt-1 increases during acute CVD as a result of alternative 
Flt-1 splicing under hypoxic conditions (Onoue et al., 2009). This hypothesis of sFlt-1 up-
regulation, along with large scale studies demonstrating the prognostic impact of sFlt-1 in 
patients with CVD and MI (Hochholzer et al., 2011; Matsumoto et al., 2012), indicates the 
potential that sFlt-1 has as a biomarker, with respect to CVD and other ischaemic conditions. 
 
Current method of measurement  
 Based on the current literature; identifying sFlt-1’s role in CVD, there have been many 
assays developed. Currently the gold standard for the detection and measurement of sFlt1 in 
the plasma is by enzyme linked immunosorbent assay (ELISA). Studies by Belgore et al. and 
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Hornig et al. outline the use of modified double-sandwich, non-competitive ELISA designs for 
the detection of sFlt-1 (Belgore et al., 2001; Hornig, Behn, Bartsch, Yayon, & Weich, 1999).  
  
In recent years the use of commercially available ELISA kits has been preferred, for 
their efficiency, as opposed to designing assays from scratch. However, most rely on the same 
electrochemiluminescence technology for detection as the ELISA assays designed by Belgore 
and Hornig. Whilst many successful ELISAs have been developed for experimental use, 
evidence for their use in a clinical setting is lacking. 
 
 A recent study has outlined the use of the Roche ELISA kit to successfully determine 
reference ranges of sFlt-1 for the assessment of pre-eclampsia (Verlohren et al., 2010), a 
hypertensive medical condition seen in pregnant women, suggesting that a similar method 
could be used following hypertensive crisis resulting from ischemic events such as in CVD. 
This being said, recent attempts to derive reference values for the prognosis of ischaemic heart 
conditions have yielded varied results. 
 
 Three recent studies obtained values of approximately 72pg/ml, 500pg/ml and 
379pg/ml respectively (Kim et al., 2011; Ky et al., 2011; Onoue et al., 2009), for patients 
suffering varying forms of ischaemic heart disease. Furthermore, Kim et al. determined that 
the level of sFlt-1 in CVD patients was not significantly different to those found in the healthy 
controls. However, it has been shown recently, that above median baseline levels of sFlt-1 
(>300 pg/ml) measured in CVD patients prior to coronary angiography, were predictive of all-
cause mortality, but not necessarily CVD events, supporting sFlt-1’s prognostic utility, but not 
its ability for prediction of CVD events (Ky et al., 2011). Therefore, due to the lack of 
consistent results and reference points, required for the prognosis of CVD in a clinical setting, 
further research is required into the development of a successful protocol for measurement and 
accurate reference standards for comparison.   
 
Evaluation of ELISA kits for quantification of sFlt-1 
 Advances in the purification and measurement of proteins have led to a better 
understanding of the molecular principles behind health and disease. From a clinical 
perspective, the selection of appropriate protein detection is essential, as the quantitative 
changes in expression must be accurately measured before a diagnostic outcome can be 
achieved. The ideal procedure for protein detection must cater for the biological question being 
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analysed, in order to achieve a low limit of detection (LOD) and an optimal signal to noise ratio 
(Westermeier & Marouga, 2005).  
 
Detection and quantification of sFlt-1 using ELISA methods has been used extensively 
to determine its potential association with CVD severity (Kim et al., 2011; Matsumoto et al., 
2012; Onoue et al., 2009). However, although an association between CVD and sFlt-1 levels 
has been established, bioanalytical methods must be optimized before valid reference standards 
can be produced for use in a clinical setting. In an article submitted by Hantash et al. (2009), a 
procedure for the optimization, validation and development of an ELISA method for the 
binding of an IgG1 monoclonal antibody to the epidermal growth factor receptor, similar to 
VEGR-1 was outlined (Hantash, Smidt, & Bowsher, 2009). Using the same method of accuracy 
assessment; assay kits for the measurement of analytes, such as sFlt-1, relating to disease 
progression may be compared and contrasted for their efficiency.  
  
The major concern of the ELISA assay is that protein levels typically vary much more 
between individuals than within one individual over time. As a result, longitudinal studies 
across a large subject group are useful in controlling for this biomarker variability across a 
population (Gonzalez et al., 2008). Furthermore, this research also demonstrates the importance 
of a stringent assay protocol and the value of optimizing antibody specificity, in order to avoid 
saturation and resulting uncertainty of analyte levels at higher concentrations. Studies using 
ELISA have shown its potential for use in candidate biomarker validation, due to its 
exceptional specificity as a result of the two antibody analyte detection system (Zangar, 
Varnum, & Bollinger, 2005).  
  
Once an appropriate selective assay has been identified methods of quantification for 
the desired biomarker can be employed. However, in order to achieve a definitive quantitative 
assay, yielding accurate and precise values to be assessed in a clinical setting, healthy and 
unhealthy reference ranges must first be defined.      
 
Assessment of clinical utility 
 Aside from the limitations of the ELISA method, all biological and environmental 
factors affecting the subject populations must be taken into account, before statements on the 
clinical outcome and early diagnosis of patients (with reference to a biomarker) can be made. 
A recent study, identifying the impact of sFlt-1 serum levels for early diagnosis in patients with 
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suspected acute MI, demonstrated that baseline characteristics of the subject population such 
as previous heart failure, smoking and diabetes played a role in the levels of biomarker 
measured and were therefore highly relevant (Hochholzer et al., 2011).  
 
Although recent findings have found a significant correlation between CVD events and 
sFlt-1 levels, reference values for healthy and CVD patients have not yet been established. 
Furthermore, values of sFlt-1 in patients at risk of CVD differ widely across various studies 
(Hochholzer et al., 2011; Kim et al., 2011; Ky et al., 2011; Matsumoto et al., 2012; Onoue et 
al., 2009). Therefore the repeatability of recent findings is difficult to verify, highlighting the 
need for development of sFlt-1 reference standards in order to ascertain reproducible results. 
 
Development of sFlt-1 standards 
 A definitive quantitative assay is defined as the use of calibrators fitted to a regression 
model in order to determine the quantitative values of unknown samples. However, such assays 
are only possible when the reference standards are well defined and fully representative of the 
endogenous biomarker (Lee et al., 2006). 
 
 It has been shown that basal levels of sFlt-1 will vary between healthy populations and 
those suffering from CVD, as well as in individuals, depending upon their current health status 
in relation to variables such as previous coronary injury, smoking or diabetes (Matsumoto et 
al., 2012). Therefore, in order to determine an individual’s or population’s potential risk via 
sFlt-1, the reference ranges established must take into account variables affecting each 
individuals sFlt-1 levels. Furthermore, in order for the ranges to be clinically and statistically 
viable, they must be obtained from a large subject group (Lee & Hall, 2009). Once these ranges 
have been established assay standards may be generated for comparison to patient levels, 
indicating potential risk of CVD events.  
 
 The recombinant form of the protein analyte is most commonly used as a reference 
material, as this serves as a relative measurement to the endogenous species. Once a standard 
curve is established from the reference material, specific parameters of the analyte material can 
be derived such as concentration and molar equivalence (Lee & Hall, 2009). Such a procedure 




1.3 Cells mediating inflammation in CVD  
 
T-cell activation in atherosclerotic plaques 
Support for the relationship between immunity and inflammation has grown 
substantially in recent years. As this knowledge has grown, it has been increasingly recognised 
that both arms of the immune response (innate and adaptive) can either exacerbate or attenuate 
aspects of atherosclerotic progression (Hansson, 2005). Furthermore, the notion that 
inflammation plays an instrumental role in plaque growth and rupture has been well supported 
by studies indicating the presence of active immune subsets in atherosclerotic lesions (George, 
2008; Hansson, 2005).  
 
The majority of data supporting activity of the innate and adaptive immune systems in 
atherosclerosis came, in recent years, from various studies of transgenic mice and from studies 
on human atherosclerotic plaque. These studies have shown the presence of activated T-
lymphocytes, B cells and dendritic cells within the lesions. Moreover, high levels of circulating 
effector molecules mediating and reflecting immune-cell action have been identified in plaque 
regions (Gounopoulos, Merki, Hansen, Choi, & Tsimikas, 2007), leading to discussion into the 
use of inflammatory system by-products as potential markers of CVD (Hansson, 2005; Libby, 
2006).  
 
As atherosclerotic lesions mature, T-cells mediate the dominant forces in inflammatory 
progression. Supporting this, all T-cell subsets (CD4+, CD8+, TCRγδ+, and NKT cells) have 
been identified in both human and murine atherosclerotic plaques (Andersson, Libby, & 
Hansson, 2010; Hansson & Hermansson, 2011; Lahoute, Herbin, Mallat, & Tedgui, 2011; 
Libby, Ridker, & Hansson, 2011; Tse, Tse, Sidney, Sette, & Ley, 2013).  
 
After proof of the presence of immune cells, and their secreted humoral components 
within the plaque, came to light an understanding of which auto-immune responses were 
operating outlined the predominance of CD4+ T cells in comparison to CD8+ T cells 
accompanied by an increased production of the cytokine IFN-γ (de Boer, van der Wal, 
Verhagen, & Becker, 1999; Stemme et al., 1995). In conjunction with these findings, patients 
with acute coronary syndromes have been shown to exhibit an altered T-lymphocyte repertoire 
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indicated by an increase in IFN-γ produced by CD4+ CD8- T-cell populations (Liuzzo et al., 
1999). 
 
 Naïve CD4+ CD8- T-cell populations include multiple lineages (Th1, Th2, Th17 and Treg 
cells) which arise in response to varying cytokine proportions in the environment. Th1 cells in 
particular occur predominantly in the presence of IL-12, which not only results in IFN-γ and 
TNF production, but also inhibits IL-4 expression, inhibiting commitment to the Th2 lineage. 
IL-18 also promotes the Th1 phenotype (Tse et al., 2013) (Fig. 7). Interestingly, Th1 cells 
exceed Th2 cells in atherosclerotic plaques and have been designated as pro-atherogenic 
(Laurat et al., 2001; Mallat, Taleb, Ait-Oufella, & Tedgui, 2009). Furthermore, supporting 
studies have shown that T-helper (Th1) subsets, known to provide immunity against 
intracellular pathogens by secreting cytokines such as IFN-γ, are expanded in acute coronary 
syndrome patients (Liuzzo et al., 2001).  
 
7,8-Dihydroneopterin (7,8NP), a marker of inflammation and immune cell activation 
produced by human monocyte-derived macrophages and dendritic cells, is induced by the pro-
inflammatory cytokine IFN-γ (Firth, Laing, Baird, Pearson, & Gieseg, 2008; Plata-Nazar & 
Jankowska, 2011). Therefore measuring 7,8NP, produced by a cellular population after Th1-
cell activation by IL-12 or IL-18, gives an indication of the potential for macrophage and 
dendritic cell activation by IFN-𝛾. This technique has proven to be useful in determining the 
macrophage and dendritic cell activation potential in inflammatory cell populations via T-cell 
activation with the synthetic protein kinase-C agonist Phorbol 12-myristate 13-acetate (PMA) 





Fig 7. T-cell lineages in atherosclerosis. Pro-atherogenic Th1: Predominantly formed in the 
presence of IL-12 and IL-18 from naïve CD4+CD8- lymphocytes. IL-12 results in transcription 
factor, T-bet activation. T-bet activation causes pro-inflammatory cytokine production such as 
IFN-γ and TNF. IL-10 and TGF-β are required for Treg commitment which have been shown 
to be athero-protective. T-cells commit to a Th2 lineage under the influence of IL-4. In a 
positive feedback loop they also produce IL-4, which inhibits IFN-γ production, as well as IL-
13 via the transcription factor GATA3. Th17 and TFH have functions that are still controversial 
and largely unknown (Tse et al., 2013).  
 
Macrophage activation in atherosclerotic plaques 
Macrophage activation has emerged as a key component of immunology, tissue 
homeostasis, disease pathogenesis and inflammation (Murray et al., 2014). The innate immune 
response of atherosclerotic initiation, involving monocyte/macrophage activation in the vessel 
wall, has been well supported as a mediating factor in cardiovascular disease progression 
followed by more specific adaptive T cell mediated responses (Moore & Tabas, 2011; Shimada, 
2009).  
 
Activation of overlying endothelial cells in a manner which recruits blood-borne 
macrophages to the arterial intima is noted as one of the key early inflammatory responses to 
apoB-lipoproteins, which may be enhanced by apoB-lipoprotein oxidation (Glass & Witztum, 
2001; Witztum & Steinberg, 2001). As a result of chemoattractant release by the activated 
endothelium, recruited monocytes are prompted to migrate across the arterial intima (Moore & 
Tabas, 2011). In support of this process, of monocyte migration, a recent study has identified 
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that blocking particular chemokines or their cognate receptors stunts atherogenesis in mouse 
models (Mestas & Ley, 2008). It is therefore likely for this reason that monocytes are found in 
abundance at the early stages of atherosclerosis. 
 
 These cells, stimulated by macrophage colony stimulating factor and other cytokines, 
differentiate becoming macrophages and upregulate pattern recognition receptors (PRRs) 
leading to exacerbated lipoprotein uptake and subsequent foam cell formation (Shashkin, 
Dragulev, & Ley, 2005) (Fig. 8). 
 
Fig 8. Endothelial activation, macrophage migration and foam cell formation. ApoB-
lipoproteins entering the arterial intima bind proteoglycans and undergo both oxidative 
modification and hydrolysis, most notably by secretory phospholipase A2 (sPLA2). This 
promotes endothelial activation, characterised by chemokine secretion and altered expression 
of adhesion molecules, leading to monocyte recruitment into the intima, these monocytes 
differentiate to macrophages and internalize both native and modified lipoproteins, 
subsequently forming foam cells. Foam cells may then further amplify lipoprotein retention 
and oxidation (Moore & Tabas, 2011). 
 
 Although it is now well documented that macrophage colony stimulating factor and 
other differentiation factors promote the differentiation of monocytes to cells with macrophage 
(and dendritic cell) like features, there is still great interest into the heterogeneity of the cells 
formed (Johnson & Newby, 2009; Paulson et al., 2010). In recent years in vitro studies, 
subjecting monocytes or macrophages to various treatments, including cytokines derived from 
different T helper cells; growth/differentiation factors; transcription factors and atherogenic 
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lipoproteins, have eluded to two major sub-groups of differentiated macrophages: Pro-
inflammatory M1 and M2 macrophages involved in resolution and repair (Johnson & Newby, 
2009; Kadl et al., 2010). However, the situation within atherosclerotic plaques in vivo is almost 
certainly more complex, highlighting the need to characterize specific molecules and molecular 
networks, which functionally contribute to the activation of macrophages in atherosclerotic 
plaques.  
 
Localized inflammation occurring as a result of continuous mononuclear cell influx, 
inefficient efferocytosis, and cell death eventually gives rise to vulnerable atherosclerotic 
plaque formation with a characteristic necrotic lipid core and a thinning fibrous cap (Thorp, 
Subramanian, & Tabas, 2011; Thorp & Tabas, 2009). Macrophages at the lesion site are the 
primary source of the inflammatory cytokine, TNF, responsible for immune cell regulation. 
TNF fuels the inflammatory cycle within the plaque, by promoting chemokine production, 
causing recruitment of more T, B (Zhou & Hansson, 1999) and monocyte cells. As well as 
increased cellular recruitment, healthy endothelial cells in vulnerable plaques have been shown 
to decrease in number as a result of TNF secretion. In vitro data indicates that macrophages 
may trigger apoptosis in endothelial cells via activation of the Fas apoptotic pathway, secretion 
of TNF and secretion of nitric oxide (Boyle, Weissberg, & Bennett, 2003).   
 
As a result of IFN-γ secretion by Th1 cells, transcription of TNF, nitric oxide and other 
inflammatory products is enhanced in macrophages (Collart, Belin, Vassalli, De Kossodo, & 
Vassalli, 1986). This links the process of Th1 activation to M1 macrophage stimulation and 
atherosclerotic exacerbation. However, pro-inflammatory molecule production is only one side 
of the macrophage response to IFN-γ. The biological antioxidant 7,8NP is also a product of 
IFN-γ induced activation in human macrophage cells. Both 7,8-NP, and especially its oxidized 
by-product neopterin, have been of substantial scientific and clinical interest recently as 
markers of macrophage activation and oxidative stress in acute and chronic inflammatory 








1.4 Neopterin and 7,8-Dihydroneoptrin 
 
Dihydroneopterin and neopterin in cardiovascular disease 
 7,8 Dihydroneopterin and neopterin, pteridine derivatives produced as a result of 
macrophage activation, are known markers of immune activation (Murr, Widner, Wirleitner, 
& Fuchs, 2002). However, markers of systemic immune system activation have also been 
associated with vascular inflammation and stenosis, which often lead to the development of 
severe cardiovascular events (Zouridakis, Avanzas, Arroyo-Espliguero, Fredericks, & Kaski, 
2004).  Recent studies have shown that neopterin levels are indeed higher in patients with acute 
MI as opposed to healthy subjects, also a significant correlation between serum neopterin and 
complex coronary artery stenosis has been found (Avanzas, Arroyo-Espliguero, Quiles, Roy, 
& Kaski, 2005). Indicating the value of neopterin as a prognostic tool of potential 
cardiovascular disease.  
 
As well as predicting the progression of inflammatory artery occlusion, neopterin has 
the potential to predict long term risk of death and recurrent coronary events, with recent studies 
indicating that high plasma neopterin levels measured after acute coronary syndromes are 
associated with increased mortality rate and future acute coronary events (Grammer, Fuchs, 
Boehm, Winkelmann, & Maerz, 2009; Nazer et al., 2011b; Ray et al., 2007; Sasaki et al., 2010). 
  
With large scale studies over the last decade providing substantial evidence confirming 
the association of neopterin with cardiovascular disease, it can be said with confidence that 
neopterin is a valuable prognostic tool for the assessment of cardiovascular risk (Fuchs et al., 
2009; Go, Chertow, Fan, McCulloch, & Hsu, 2004). Furthermore, the prognostic utility of 
neopterin also provides the potential for it to be used as a comparative marker for potential new 
biomarkers of cardiovascular disease. 
 
Synthesis of 7,8NP and neopterin 
7,8NP (IUPAC: 2-amino-6-[(1S,2R)-1,2,3-trihydroxypropyl]-7,8-dihydropterin4(3H)-
one) is synthesised by the biopterin pathway of human myeloid cells such as: monocytes, 
macrophages, dendritic cells and to a lesser extent fibroblasts, endothelial cells and kidney cells 
(Murr et al., 2002; Wirleitner et al., 2002). Through an IFN-γ induced enzyme, guanosine 
triosephosphate cyclohydrolase-1 (GTPCH-1), GTP is primarily hydrolysed to 7,8NP 
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triosephosphate. Reflecting the ubiquity of the pathway, in producing alternate reaction 
products, 7,8NP triosephosphate is then dephosphorylated by a non-specific phosphatase 
forming 7,8NP (Fuchs et al., 2009; Walter, Schaffner, & Schoedon, 2001).  Alternatively, in 
non-primate and non-human cells, the triosephosphate group of 7,8NP triosephosphate would 
be removed by the enzyme 6-pyruvol-tetrahydropterin synthase (PTS) prior to further 
processing by sepiapterin reductase (SR) to tetrahydrobiopterin (Walter et al., 2001). However, 
due to a lack of PTS activity in human and primate leukocyte cells 7,8NP triosephosphate is 




Fig 9. Biological 7,8NP triosphosphate pathways. GTPCH-1 initially converts GTP to 7,8NP 
triosephosphate, in macrophages, once stimulated by IFN-γ. 7,8NP triosephosphate 
accumulates due to PTS deficiency in humans. This results in subsequent dephosphorylation 
of 7,8NP triosephosphate producing 7,8NP. 7,8NP may then be further oxidised to neopterin 
(Shchepetkina, 2013). 
 
7,8-NP diffuses out of activated macrophages where it can be readily oxidized (in the 
plasma or within the plaque) (Widner, Mayr, Wirleitner, & Fuchs, 2000), by a range of 
electrophilic molecules, forming either neopterin or 7,8-dihydroxanthopterin (7,8-DXP). 
Mainly mediated physiologically by hypochlorous acid (HOCl), neopterin production, like 7,8-
DXP occurs during oxidative stress (Fig. 9). However, 7,8-DXP production is not exclusive to 
7,8NP oxidation, since it is the main product of most biological pterins it doesn’t primarily 
reflect monocyte and macrophage activation. (Vásquez-Vivar, 2009; Widner et al., 2000). 
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Neopterin however, being solely derived from 7,8NP (Fuchs et al., 2009), specifically 
highlights oxidative stress at points of immune system activation. 
 
 
Fig 10. Oxidation of 7,8NP. The oxidation of 7,8NP to neopterin occurs primarily by the 
action of HOCl. The processing of 7,8-DXP occurs predominantly via the action of peroxyl 
and hydroxyl radicals (Gieseg et al., 2009).  
 
Clinical utility of 7,8NP and neopterin   
 In contrast to 7,8NPs anti-oxidant properties several studies have shown that neopterin 
can act as a pro-oxidant, enhancing oxidant production thereby promoting cell death, 
potentially leading to plaque rupture (Sugioka et al., 2010). This has led to a direct association 
of neopterin with plaque instability in cardiovascular disease subjects (Zouridakis et al., 2004). 
Furthermore, there is increasing evidence of neopterins clinical efficacy as a prognostic marker 
of cardiovascular events (Avanzas et al., 2005; Avanzas & Kaski, 2009; Fuchs et al., 2009; 
Nazer et al., 2011b).  
 
With IFN-γ being the primary stimulant for 7,8NP production a link between 
immunocompetent cells may be established through monitoring of 7,8NP (Adachi et al., 2007). 
For this reason, measurement of 7,8NP and to a greater extent its oxidised product neopterin 
are routinely used as markers of immune system activation in patients suffering 
21 
 
from infections, autoimmune diseases, malignancies, allograft rejection, cardiac failure, renal 
failure and cardiovascular disease (Adachi et al., 2007; Berdowska & Zwirska‐Korczala, 2001).  
 
Stable ratios of 7,8NP to neopterin for arterial (2:1) and venous blood (3:1) have been 
well established in vivo further highlighting the utility of both molecules as biomarkers of 
inflammatory cell activation (Fuchs et al., 1989; Weiss et al., 1992). Neopterin levels measured 
in healthy subjects have been reported at 6.7 ± 1.5 nM in blood (Murr., Schroecksnadel, 
Schonitzer, Fuchs, & Schennach, 2005). Whereas healthy levels of 7,8NP vary around ≈5.8 
nM (Flavall, Crone, Moore, & Gieseg, 2008) which is likely a reflection of 7,8NPs instability 
relative to neopterin. However, what makes the two molecules valuable biomarkers of 
cardiovascular disease is that significantly elevated levels have been extensively measured in 
patients during cardiovascular events, reflecting the Th1 activity and inflammatory aspects of 
the disease (Avanzas & Kaski, 2009). 
 
 Higher baseline levels were recently found in females who experienced coronary 
events, during follow up, after being admitted for chronic stable angina (CSA) (Garcia-Moll, 
D. Cole, E. Zouridakis, & J. Kaski, 2000). Endorsing these results, two subsequent studies 
demonstrated that neopterin levels, in hypertensive patients with typical angina, were an 
independent predictor of major adverse coronary events during a 1-year follow-up period. 
Moreover, with increasing neopterin levels a significant gradual increase in the number of 
adverse events was seen during follow-up. Patients in the highest neopterin group (> 7 nmol/L) 
had a three-fold higher risk of developing adverse cardiovascular events (Avanzas et al., 2004; 
Avanzas et al., 2005). These studies, among numerous others, add to the cumulative evidence 
in recent years indicating that neopterin, a marker of macrophage activation, may be a useful 
tool in the assessment of cardiovascular risk.  
 
As neopterin is already known as a valid biomarker of inflammatory events it may be 
used in comparison to sFlt-1 to determine its diagnostic benefit. Since a correlation between 
cardiovascular events and neopterin has already been established (Avanzas et al., 2004; 
Avanzas et al., 2005; Garcia-Moll, Coccolo, Cole, & Kaski, 2000; X. Garcia-Moll, D. Cole, E. 
Zouridakis, & J. Kaski, 2000; Nazer et al., 2011b; Ray et al., 2007), analysis of neopterin levels 
in conjunction with sFlt-1 levels may provide further power to biomarker risk assessment with 
respect to CVD. In support of this, recent studies have compared other markers of inflammation 
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such as C-reactive protein (CRP), eluding to the possible use of a combination of conventional 
markers for risk stratification (Zethelius et al., 2008).   
 
1.5 Objectives of study  
 
Multiple biological pathways have been implicated in the aetiology of CVD including, 
but not limited to, inflammation, hypoxia and oxidative stress. Identifying markers of these 
pathway outcomes or processes may facilitate risk prediction and development of treatment 
regimens (Stoner et al., 2013). However CVD is now known to involve multiple complex 
mechanisms, such that there is no single definitive biomarker of cardiovascular risk. However, 
the function of many CVD biomarkers overlap. Furthermore, some of these markers are better 
suited to identifying the particular pathogenesis of specific cardiovascular events. Therefore, 
two potential outcomes of CVD biomarker use can be derived; biomarkers can be selected to 
identify a specific stage of CVD or alternatively simultaneous measurement of multiple 
biomarkers can give a more detailed overview of the specific nature of cardiovascular events.  
 
In order for biomarkers to be used in conjunction, for risk prediction and diagnosis, 
appropriate analysis must be made to determine whether biomarkers measured together give 
compounding evidence of cardiovascular risk and furthermore whether measurements can 
provide predictive results. Biomarker levels typically vary much more between individuals 
than within one individual over time. As a result, longitudinal studies across a high subject 
group are useful in controlling for this biomarker variability across a population (Gonzalez et 
al., 2008). 
 
This study focussed predominantly on of sFlt-1, neopterin and 7,8 NPs potential for use 
alone and in conjunction with other biomarkers of CVD.  
 
With the aim to identify a potential prognostic use for sFlt-1, neopterin and 7,8-NP, 
plasma samples from 514 patients, who were stable after experiencing a CVD event, were 
assayed. These patients’ medical admissions were followed up for a median period of 8 years. 
Plasma from 27 patients was also taken prior to carotid endarterectomy procedures and 
analysed to determine the levels of sFlt-1 and other biomarkers produced in late stage CVD.   
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As well as determining the prognostic utility of s-Flt-1, this study also aimed to assess the 
pathophysiology of CVD in terms of sFlt-1, neopterin and 7,8-NP production, via analysis of 
atherosclerotic plaque, which may give insight into the association between inflammation and 

























Materials and Methods 
 
2.1 Reagents, kits, media and buffers 
 
Reagents 
All reagents were prepared to the standard of analytical grade or better. All solutions 
were prepared with de-ionised water, which was purified using a milli-Q ultrafiltration system, 
referred to as nano-pure water. 
 
7,8-Dihydroneopterin triphosphate (7,8NP)  Schricks Laboratory, Switzerland 
Acetic acid (glacial)     Scharlau Chemie S.A., Spain 
Acetonitrile (ACN)     J.T. Baker, NJ, USA 
Ammonium phosphate dibasic (AmPO4)  Sigma-Aldrich Co. LLC, NZ 
Ascorbic acid      Sigma Chemical Co., MO, USA 
Dimethyl sulfoxide (DMSO)  BDH Lab Supplies, England 
Ethanol      BDH Lab Supplies, England 
Hydrochloric acid (HCL)    BDH Lab Supplies, England 
Iodine (I)      BDL Lab Supplies, England 
Lactate  Sigma-Aldrich Co. LLC, NZ 
Leukine® (GM-CSF)     Sigma-Aldrich Co. LLC, NZ 
Methanol (MeOH)     Merck, Darmstadt, Germany 
Neopterin (NP)     Schircks Laboratory, Switzerland 
Orthophosphoric acid     Sigma Chemical Co., MO, USA 
Potassium Iodide (KI)     May & Baker Ltd, England 
Phorbol 12-myristate 13-acetate (PMA)  Sigma Chemical Co., MO, USA 







Lactate assay kit     Roche diagnostics, Indianapolis,                
Indiana, USA 
sFlt-1 ELISA kit      R&D Systems, Minneapolis, Minnesota 
12 well adherent cell culture plate    Cell star®, 
Cell culture multi well plate, 12 well,   Greiner Bio-one, Kremsmünster, Austria 
 
Media 
Cell/plaque culture media: 
Penicillin (1000U)/streptomycin (1000 µg/ml) solution Invitrogen, Life technologies, NZ 
RPMI (Roswell Park Memorial Institute) 1640  Sigma-Aldrich Co. LLC, NZ 
10% Human serum      Canterbury University,  
Christchurch, NZ 
 
Buffers & solutions 
Ammonium Phosphate HPLC buffer: 
NH4PO4 (dibasic), 2.64g, was added to 900 ml of nanopure grade water were combined 
in a 1000ml beaker and mixed on a magnetic stirrer. Once all of the ammonium phosphate had 
dissolved the pH of the solution was adjusted to 2.5 with concentrated phosphoric acid added 
dropwise with a Pasteur pipette. The solution was then made up to 1000ml with nanopure water 
and mixed well. In order to remove contaminants the 1000ml of buffer was then vacuum 
filtered through a 0.45 m membrane filter (Phenomenex), into a 1000ml Schott bottle, using 
a Millipore filter system.  
 
Acidic iodide solution: 
Solid iodine, 2.7g, and 5.4g potassium iodide were added to 35 ml of water. 
Concentrated HCl, 4.37mL, was then added to make up to a final volume of 50 ml (5.4% I2 / 
10.8% KI in 1M HCl).   
This solution forms a triodide (I3
-











Ascorbic acid solution: 
Ascorbic acid, 1.057g, was dissolved in in 10 ml of water to give a 0.6M solution. Note 
that ascorbic acid in solution does not keep for more than a day as is oxidised easily, especially 
in the presence of light. Therefore it was prepared fresh and used within an hour of preparation 
whilst being keep covered with aluminium foil. 
 
IFN-γ solution:  
IFN-γ was diluted in PBS with 2.5% sucrose (sterile-filtered), as per manufacturer’s 
instructions, to give a solution of 10,000 U/ml. This stock solution was aliquoted into 500 µl 
aliquots and stored at -20ºC until used. A new vial was used after one vial was defrosted 2 
times as IFN- γ activity was lost after 2 freeze-thaw cycles. 
 
PMA solution: 
PMA (99% pure) was dissolved in DMSO to produce 5mM, 20µl stock aliquots. Before 
use the 20µl stock was mixed with 980µl of de-ionised water to make a 100µM solution, then 
50µl of this solution was then added to 5950µl of de-ionised water to make a final concentration 
of 200nM. This final solution was never kept for more than a day.   
 
2.2 Plaque culture technique 
 
Endarterectomy plaque and plasma collection:  
Plaque and plasma were collected from the Christchurch General Hospital, under the 
supervision of Prof. Justin Roake, from patients undergoing a carotid endarterectomy 
procedure. Fresh plaques were kept on ice between transfers from the hospital to the University 
of Canterbury School Of Biological Sciences. Plaque obtained was either cultured within the 
hour of removal from the patient or otherwise frozen at -80°C. The plasma collected was 
centrifuged at 2000 rpm (MultifugeSR, Biostratergy, New Zealand) for 12 minutes in order to 
pellet the red blood cells. The supernatant was then transferred to two labelled 1.7 ml centrifuge 
tubes and stored at -80◦C. 
 
Sterile conditions: 
All plaque and cell culturing was carried out under sterile aseptic conditions under a 
class II biological safety hood. (Clyde-Apex BH 200). All equipment was either sterile–bought 
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plastic ware (Falcon, Bector Dickinson & Co.; Nunc, Nalge Nunc International; Greiner, 
Greiner Bio-one, Neuburg, Germany) or was sterilised via autoclaving (15 min, 121◦C, 15 psi). 
All media and solutions added to cells and plaque was sterilised via autoclaving. The cells and 
plaque were kept at 37◦C in a humidified atmosphere calibrated to 5% carbon dioxide: 95% air 
(Sanyo Electric Co. Ltd, Japan). All items were also sprayed with 70% ethanol (30% distilled 
water) before insertion into the class II safety hood.  
 
Collection of human serum for use in Culture media: 
Human plasma was collected, under ethics approval CTY/98/07/069 granted by the 
Upper South (B) Regional Ethics Committee, from anonymous haemochromatosis patient 
blood. This blood was collected into 450 ml vacuum-sealed bags, for the University of 
Canterbury, by the New Zealand Blood Bank (Riccarton Branch, Christchurch).   
Blood was kept at room temperature for two hours to allow for clotting to occur. The blood 
was then transferred to 4◦C overnight to allow for separation of the human serum from the clot. 
 
The following day separated serum was transferred to 50 ml centrifuge tubes using a 
20 ml syringe. The tubes were then centrifuged at 1000 g for 15 minutes (MultifugeSR, 
Biostratergy, New Zealand) in order to pellet the remaining red blood cells.  
The clear serum was then transferred to new 50 ml centrifuge tubes whilst taking care not to 
transfer any of the pelleted cells. If red blood cells remained then the centrifuge procedure was 
repeated. 
 
The serum was then transferred to a -80◦C freezer for long term storage. The serum was 
generally used within a 3 month period. 
 
Preparation of cell and plaque culture medium: 
Powdered RPMI was dissolved in nano-pure water with sodium bicarbonate (NaHCO3) 
according to manufacturer’s instructions. The pH was then adjusted to 7.4 by the addition of 
11.4 M hydrochloric acid (HCl). The solution was then filtered through a 0.22µm Millex®-
GP50 filter and peristaltic pump (CP-600, life technologies, Maryland, USA) before transfer 
into sterile 500 ml bottles. 5.6 ml of the combined 10000 U/ml penicillin and 10000 µg/ml 
streptomycin was then added. The final solution was then kept at 4◦C until it was required for 
plaque or cell culture.  
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Before use in plaque or cell culture 45 ml aliquots of the RPMI 1640 
penicillin/streptomycin mixture were transferred to 50 ml sterile centrifuge tubes. 5 ml of 
defrosted human serum was then added before storage at 4◦C. The 50 ml cell culture solutions 
were always used within 1 week of preparation. 
 
Plaque culture procedure: 
Under sterile conditions the freshly excised atherosclerotic plaques were initially 
photographed before being sliced into 2 mm sections using a sterile surgical blade. Sections 
were then put into, previously weighed, sterile 2 ml centrifuge tubes. These tubes containing 
the sections were then weighed to determine the plaque weight. 
 
Each plaque section was then transferred to a well on a 12 well adherent cell culture 
plate (Cell culture multi well plate, 12 well, Cell star®, Greiner Bio-one, Kremsmünster, 
Austria). After transfer to the cell culture well 2 ml of the plaque culture RPMI 1640 media 
was added. The lid of the cell culture plate was labelled, according to the order in which the 
plaque sections were cut from the whole plaque, before being incubated at 37◦C in a humidified 
atmosphere calibrated to 5% carbon dioxide and 95% air (Sanyo Electric Co. Ltd, Japan) for 
24 hours. 
 
2.3 Human monocyte derived macrophage (HMDM) culture  
 
Lymphocyte isolation:  
Human plasma was collected, under ethics approval CTY/98/07/069 granted by the 
Upper South (B) Regional Ethics Committee, from anonymous haemochromatosis patient 
blood. This blood was collected into 450 ml vacuum-sealed bags, for the University of 
Canterbury, by the New Zealand Blood Bank (Riccarton Branch, Christchurch). 
  
Blood was initially inverted 10 times to ensure an adequate distribution of red blood 
cells existed within the bag. After inversion the bags were sprayed with ethanol and separated 
into 50 ml falcon tubes. The 50 ml falcon tubes were subsequently centrifuged, at 1000 g in 





The serum plasma was removed via syringe down to the 30ml mark of the falcon tube. 
Approximately 15-17.5 ml of buffy coat was then transferred, via mixing cannula in 
combination with a 20 ml syringe, into a new 50 ml falcon tube (erythrocytes may also be 
transferred but will be removed in subsequent processing). 
 
  The newly transferred buffy coat was then mixed with 17.5 ml of PBS and gently 
inverted. Using a mixing cannula, attached to a 20ml syringe, 15 ml of Lymphprep® solution 
was carefully added beneath the buffycoat/PBS mixture (a new cannula is needed for each tube 
so not to contaminate the Lymphprep®).  
  
The 50 ml buffy coat/PBS/Lymphprep® tubes were once again centrifuged at 1000 g at 
18◦C for 20 minutes. This process pellets the remaining red blood cells and forms a floating 
monocyte/lymphocyte layer approximately halfway down the tube. This monocyte layer was 
then transferred, using a mixing cannula attached to a 20 ml syringe, to new 50 ml flacon tubes. 
 
Each tube was filled to 45 ml with PBS, re-suspending the cells, before centrifuging for 
15 minutes at 500 g. This PBS and centrifuge step was then repeated another two times. 
After the final centrifuge step, cells were re-suspended in 30 ml RPMI and counted. The cells 
were counted by adding 20 µl of cell suspension to 180 µl of trypan blue before transfer to a 




Fig. 2.1 Post-centrifuged 
blood. After centrifuging at 
1000 g for 30 minutes the 
erythrocytes form a pellet. 
The buffy coat is the fraction 
of an anti-coagulated blood 
that contains most of the 




HMDM seeding and feeding: 
After counting, cells were transferred to Cell star® 12 well adherent cell culture plates 
before incubation at 37◦C, in a humidified atmosphere calibrated to 5% carbon dioxide and 
95% air, for 40 hours. This allows for T-cell death and platelet adhesion to occur. 
After incubation, cells were transferred to 50 ml falcon tubes (making sure to pipette 
thoroughly to remove any monocytes resting on the plate bottom) and spun at 500 g in room 
temperature for 15 minutes. 
  
The supernatant was then removed and the cell pellet was re-suspended, prior to 
counting once again with trypan blue, whilst adjusting to ensure concentrations of 5×106 
cells/ml RPMI with 10% heat inactivated human serum (HIHS). 1 µL of 25 µg/ml GM-CSF 
(Leukine® made up in nanopure water) per 1 ml of cell suspension was also added. For 
example: 25×106 cells/ml = 720×106 total cells. This is enough to make 150 ml at 5×106 
cells/ml. In this case 10 ml of the concentrated cells would be added to three different tubes. 
35 ml would then be added along with 5 ml of HIHS and 50 µl of GM-SCF solution to give 
three tubes each containing 50.05 ml with a concentration of 25×106 cells/ml. 
 
1 ml of the 25×106 cells/ml suspension was then added to each well on Cell star® 12 
well adherent cell culture plates and incubated at 37◦C, in a humidified atmosphere calibrated 
to 5% carbon dioxide and 95% air. The cells media was changed approximately every 3 days 
leaving approximately 200 µl of the old media in the wells allowing adhered cells to remain. 
   
2.4 IFN-γ stimulation of macrophages and live plaque  
 
After the plaque sections had been incubated for 24 hours (Macrophages 11 days after 
seeding) the media was removed using a 1ml pipette. This media was transferred to two 1.7 ml 
tubes, labelled with the appropriate incubation time stamp, before transfer to storage at -80◦C.  
 
New media (2 ml or 1 ml for macrophages) was then added to each well before 
incubation under the same conditions for another 24 hours. After this second 24-hour period 
media was again stored at -80◦C. This time only 1900 µl (900 µl for macrophages) of media 
was added to each well, along with 100 µl (50 µl for macrophages) of the 10000 U/ml IFN-γ 
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stock solution (which had been previously defrosted), to give a final concentration of 500U/ml 
in each well.  
 
Plaque sections and macrophages were then incubated under the same conditions for a 
further 24 hours. Media was taken after this 24-hour incubation and the addition of IFN-γ to 
the media was repeated once more along with one final 24-hour incubation period. After the 
last incubation period the final media was collected and stored, for future analysis, along with 
the other 24-hour periodical samples at -80◦C. 
 
Lane 0  1 (24) 2 (48) 3 (72) 4 (96) 




2.5 PMA stimulation of live plaque  
 
After the plaque sections had been incubated for 24 hours the media was removed using 
a 1 ml pipette. This media was transferred to two 1.7 ml tubes, labelled with the appropriate 
incubation time stamp (24 hours), before transfer to storage at -80◦C. 1.6 ml of new media was 
then added to each well, along with 400 µl of the 1000 nM PMA solution, to give a final 
concentration of 200 nM PMA per well, before incubation under the same conditions for 
another 24 hours. The same media change, 200 nM PMA addition and 24 hour incubation 
period was repeated twice more. After the last incubation period the final media was collected 
and stored, for future analysis, along with the other 24-hour periodical samples at -80◦C. 
 
 
Lane 1 Lane 2 Lane 3 Lane 4 






Alternative procedure:  
The same procedure was carried out on other plaque sections however the final media 
change contained 100 µl of 10000 U/ml IFN-γ and 1900 µl of cell culture media, rather than 
the previously added 200 nM PMA.  
  
 
Lane 0 1 (24) 2 (48) 3 (72) 4 (96) 
PMA None 
 
200nM 200nM 200nM Final 
collection 
 
2.6 Lactic acid assay  
 
The lactic acid content of plaque and cell cultures was measured using a method derived 
from the Roche Diagnostics Lactic Acid Assay Kit (Roche Diagnostics, Indianapolis, Indiana, 
USA). The kit primarily employs an enzyme, lactate oxidase (LOD), for the conversion of 
lactic acid to pyruvate and hydrogen peroxide. Peroxidase (POD) was then used to catalyse the 
reaction between hydrogen peroxide and a hydrogen donor.  In the presence of 4-
aminoantipyrine (AAP) this produced a purple chromogen, with intensity proportional to the 
concentration of lactic acid present in the media.  
 
Live cells in culture utilize supplementary glucose to produce lactic acid. Therefore, 
this measurement of lactic acid gave an indication of active metabolism by cells. The kit can 
detect between 0.22 and 15.5 mM lactic acid. 
 
Lane 1 Lane 2 Lane 3 Lane 4 






Two working reagents are provided in the kit. Reagent 1 (R1) contains the hydrogen 
donor, ascorbate oxidase, buffers and preservatives. Reagent 2 (R2) contains AAP, lactate 
oxidase, horse peroxidase, buffers and preservatives. 
 
In order for the kit to be used in 250 µl 96 well plates (96 well, Greiner Bio-one, 
Kremsmünster, Austria) volumes of both the sample and the reagents had to be reduced from 
those in the standard lactic acid assay method. 
 
One blank of R1 with nanopure de-ionised water and another containing RPMI R1 and 
R2 were injected into the first two wells of a 96 well plate. A working standard curve was then 
established using lactate diluted in de-ionised water to seven standards between 0.22 and 15.5 
mM (limits of detection). These standards were then injected, in duplicate, into a 96 well plate 
along with one blank of R1 with de-ionised water and another containing RPMI R1 and R2  
 
The standard method required that 840 µl of R1 and 168 µl of R2 be added to 20 µl of 
sample (or standard). However, these volumes would not fit in the wells. Therefore, one fifth 
of each solution was used. 20 µl of sample (or standard) was added to 80 µl of R1 in a 1.5 ml 
centrifuge before it was vortexed for 30 seconds. 20 µl of this mixture, containing 4 µl of 
sample and 16 µl of R1, was then pipetted into the desired wells. 
The remaining 152 µl of R1 was then added to the wells. Once all samples and R1 had been 
added to the wells 33.6 µl of R2 was added to each well. The plate was then covered and left 
to incubate and mix on a plate rocker for 30 minutes.  
The absorbance at 660 nm of each sample and standard well was then determined using a plate 
reader. 
  
The lactic acid levels found in the cell culture blank were subtracted from those found 
in the plaque culture and cell culture samples to give the levels of lactate produced by the cells 
and plaque alone.  
 
2.7 sFlt-1 assay  
The sFlt-1 content was measured in plaque media, cell cultures and plasma using a 
method derived from the R&D systems sFlt-1 ELISA kit (R&D Systems, Minneapolis, 
Minnesota). The assay employes a monoclonal antibody, specific for sFlt-1, which is pre-
coated onto a 96 micro well plate. Any sFlt-1 is bound to the immobilized antibody. An 
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enzyme-linked polyclonal antibody specific to sFlt-1 is then added which also binds the sFlt-
1. A corresponding substrate to the enzyme is then added which prompts the development of a 
colour change in the wells. The colour developed is proportional to the amount of sFlt-1 in 
solution. 
 
Using the sFlt-1 standard provided 8 sFlt-1 standard concentrations were prepared 
ranging from 30 pg/ml to 2000 pg/ml using the supplied calibrator diluent (RD6-10). Calibrator 
diluent was also used as a blank. Quality control standards were also prepared from heat-treated 
human plasma spiked to 100 pg/ml. 
 
Defrosted plaque media and plasma samples were thoroughly vortexed and centrifuged 
for 15 minutes at 1000 g. 
 
Whilst wearing a face mask to avoid contamination 100 µl of assay diluent (RD-68) 
was added to each well. This was followed by the addition of 100 µl of standard, control, or 
sample per well. The plate was then covered with an adhesive strip and left to incubate at room 
temperature for two hours on a plate rocker.  
 
Using an auto-washer and the wash buffer provided each well was washed a total of 
four times. After the last wash any remaining wash buffer was aspirated from the wells. 
200 µl of sFlt-1 conjugate was then added to each well before the plate was again covered and 
left to incubate on the plate rocker for another two hours. After the incubation period the 
washing and aspiration procedure was repeated.  
 
A 200 µl aliquot of substrate solution was then added before a final incubation in the 
dark for 30 minutes.  
 
Finally 50 µl of stop solution was added to each well, prompting a colour change from 
blue to yellow. The optical density of each well was determined within 30 minutes of stop 
solution addition using a microplate plate reader set to 450 nm 
 
Alternative sample preparation: 
Levels of sFlt-1 in endarterectomy plasma samples were determined to be far greater 
than the limit of detection for the ELISA kit. These samples were therefore diluted (1:20) with 
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calibrator diluent. Subsequently, levels determined from the standard curve were multiplied by 
20. 
 
2.8 Neopterin and dihydroneopterin HPLC method 
 
High performance liquid chromatography (HPLC), an analytical technique used to 
separate specific components of a complex mixture based on their chemical and physical 
properties, was used to analyse pterin levels in both plasma and culture samples. The HPLC 
system used (Shimadzu Corporation, Japan) utilized a LC20AD pump in conjunction with an 
on-line de-gasser, SIL-20AC temperature controlled autosampler, CTO-20 column oven and a 
RF10AXL fluorescence detector. 
 
Peaks generated by the column separation were integrated using LC solutions software 
(Shimadzu Corporation, Japan). The method used was based on that used by Shricks 




A mixture of 20% methanol and 80% water was initially pumped through the HPLC at 
1 ml/minute for 15 minutes in order to wash the lines. After the 15 minute wash, line A was 
purged with water for three minutes before it was purged with pre-prepared AmPO4 (20 mM, 
pH 2.5). AmPO4/10% ACN was then left to pump at 1 ml/minute for 5 minutes or until the 
pressure stabilized. The Neopterin SCX column was then connected and left to pump at 1 
ml/minute. A Luna strong cation exchange (SCX) 250×4.6 mm column (Phenomenex, USA) 
was employed as the stationary phase, to retain and separate the injected samples. Making sure 
that the column oven was set to 30◦C, the RF10AXL fluorescence detector, set at 353 nm 
excitation and 438 nm emission wavelengths, was switched on before the pressure was left to 
stabilize.  
 
Neopterin standard curve preparation 
In this definitive quantitative assay neopterin calibrators (standards) were fitted to a 
regression model in order to determine the quantitative value of neopterin in unknown samples. 
The neopterin linear regression (standard) curve, consisting of serially diluted concentrations 
of a 100 µM stock solution with nanopure de-ionised water (Schircks Laboratory, Switzerland), 
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ranged between 10 nM and 100 nM. 10 µl of these standards were then injected, in duplicate, 
into the HPLC running at 1ml/min AmPO4/10% ACN. These standards were expressed 
computationally, by the LC solutions software as peaks. The area under these peaks was 
proportional to the amount of neopterin present in the solution. Therefore a standard curve was 
generated by plotting area on the Y-axis and neopterin concentration on the X-axis. From this 
curve unknown concentrations of neopterin were derived (Fig 13). 
 
0 5 0 1 0 0
0
5 0 0 0 0
1 0 0 0 0 0















Fig 2.4. neopterin linear regression (standard) curve 
 
Acidic iodide oxidizing potential testing: 
In order to make sure that the acidic iodide stock solution could convert 7,8-NP ≥98% 
to neopterin it had to be tested before use. Using a highly sensitive microbalance 2 mg of pure 
7,8-NP (Schricks Laboratory, Switzerland) was weighed out into a cap cut from the top of a 
1.7 µl centrifuge tube. The cap was then transferred to a 20 ml, aluminium foil covered, bottle 
with 10 ml of the 20 mM, pH-2.5 NH4PO4and sonicated until dissolved. The concentration of 
7,8NP was then calculated using the molecular weight of 7,8NP (MW=253). The 7,8NP 
containing sample was oxidised using 40 µl of the acidic iodide for 15 minutes in the dark, 
before 20 µl of ascorbic acid was added to reduce the remaining acidic iodide. 10 µl of this 
sample was then injected, in duplicate, into the HPLC running at 1ml/min AmPO4/10% ACN. 
The concentration derived was then compared to the concentration of 7,8NP added to 




Plasma and cell culture sample preparation and injection: 
Neopterin:  
100 µl of defrosted plasma or culture was initially transferred to 1.5 ml centrifuge tubes 
with 100 µl of 100% ACN. The tubes were then vortexed thoroughly for five seconds before 
being centrifuged at 20,300 g for 5 minutes at 4◦C. 100 µl of the resulting supernatant was then 
loaded into HPLC vials. 10 µl of each loaded sample was then injected into the HPLC for 
analysis. 
 
Total pterin:  
100 µl of defrosted plasma or culture was initially transferred to 1.5 ml centrifuge tubes 
with 100 µl of 100% ACN. The tubes were then vortexed thoroughly for five seconds before 
being centrifuged at 20,300 g for 5 minutes at 4◦C. 40 µl of pre-tested acidic iodide solution 
was then added to the supernatant. It was then left to incubate in the dark at room temperature 
for 15 minutes. Following incubation 40 µl (20 µl for cell culture) of ascorbic acid was added 
to the samples, to reduce the iodine, prompting a colour change from brown to clear. The 
samples were subsequently centrifuged at 20,300 g for 5 minutes at 4◦C before 100 µl of the 
resulting supernatant was loaded into HPLC vials. 10 µl of each loaded sample was then 
injected into the HPLC for analysis. 
 
2.9 Statistical methods  
All statistics on data from the CDCS cohort were calculated using the IBM SPSS 
statistics 19 software. (SPSS Inc., Armonk, New York). All statistics on data from the 
endarterectomy cohort were calculated using Graph Pad Prism 6 software (GraphPad Software 
Inc., La Jolla, California). 
 
Patient population  
CVD patients (n=514), who were admitted to Christchurch Hospital following a 
cardiovascular event between July 2002 and August 2007, were enrolled in the study to 
evaluate potential markers of mortality following a cardiovascular event. Patients were 
recruited into the study according to the following inclusion criteria; ischemic discomfort plus 
one or more of electrocardiogram changes (ST segment depression or elevation of at least 0.5 
mm, T-wave inversion of at least 3 mm in at least three leads, or left bundle branch block), 
elevated levels of cardiac markers, a history of coronary disease, or were aged at least 65 years 
in patients with diabetes or vascular disease. Patients were excluded from the study if they had 
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a severe comorbidity that limited their life expectancy to less than 3 years, or were aged <18 
years. Clinical events were investigated upon re-admittance to hospital where all cause death 
(ACD), CVD death and total cardiovascular events (TCVE) were the major study end points.  
 
Of the 514 patient cohort, 365 were male and 149 were female. The clinical parameters 
assessed largely focussed on the biomarkers sFlt-1, neopterin and 7,8NP. These biomarkers 
were compared to BNP, measured previously in the same cohort by Endolab of the 
Christchurch Heart Institute, along with age at baseline, gender, alcohol consumption, diastolic 
blood pressure, diastolic, tobacco usage, statin usage, type two diabetes status and bodyweight 
(Refer to table 3.1.1 in Results).  
 
sFlt-1 data, prior to forming statistical models, was compared to data obtained in a 
similar study by Matsumoto et al. (2013) in order to determine the relative statistical power of 
the dataset. Statistical power was calculated to determine the significance of the data in terms 
of sample size and the ability of the data to test the null hypothesis. 
 
General linear model analysis  
Multiple univariate general linear models were used to assess the hypothesis that 
variables commonly associated with CVD exhibit a significant relationship to the biomarkers 
sFlt-1, neopterin, 7,8NP and total neopterin. A type III sum of squares method (equivalent to 
Yates' weighted-squares-of-means technique) was employed to deal with the unbalanced 
models.  
 
Cox regression proportional hazards model and Kaplan-Meier analysis 
Variables were split into above and below median values before Kaplan-Meier analyses 
were performed to evaluate the incidence of mortality and CVD during the follow up period. 
To evaluate significant difference at different time points in the survival curves, each curve 
was subjected to Log-rank, Breslow and Tarone-Ware analysis. Cox proportional hazard 
regression analyses were performed to evaluate the relationships between age at baseline, the 
biomarkers sFlt-1, neopterin, 7,8 NP, and BNP with respect to TCVE and ACD. All tests were 






Endarterectomy statistics  
Blood samples from the endarterectomy cohort were obtained immediately prior to the 
carotid endarterectomy procedure at Christchurch Hospital, by Prof Justin Roake and 
associates of the Vascular Surgery Department, after which extracted plasma was analysed for 
sFlt-1, neopterin, 7,8 NP and total neopterin. In the 27 patient cohort, 19 were male and 8 were 
female. The clinical parameters assessed largely focussed on the biomarkers sFlt-1, neopterin 
and 7,8 NP (Refer to tables 6.1 and 6.2 in Appendix). 
 
A PrismTM Standard 2 tailed T-test with Tukey post-hoc was used to analyse the data 
obtained from the analysis of Endarterectomy patient plasma.  
 
SPSSTM Bivariate analysis of the plasma data was used to obtain correlative statistics 
on sFlt-1, neopterin, 7,8 NP and total neopterin. 
 
PrismTM 2 way ANOVA was used to analyse the variance between subgroups in the 






3.1 Cardiovascular disease cohort study (CDCS) 
Acute coronary syndrome patient plasma was used to assess the clinical utility of sFlt-
1 in comparison with neopterin and 7,8NP, total neopterin levels. The plasma was collected 
from patients in a stable condition following an acute coronary syndrome event (Table 3.1.1). 
Each patient’s clinical outcome was followed using hospital and National Health Information 




















34.0 93.0 39.0 91.0 68.8±0.5 68.48±1.1 365 149 
Height 
(cm) 
147.0 192.0 147.0 192.0 186.3±0.4 168.7±0.8 365 149 
Weight 
(Kg) 




0.3 60.0 0.3 58.0 9.9±1.0 9.0±1.1 365 149 
Systolic 
BP 
80.0 230.0 80.0 230.0 128.1±1.0 131.9±2.2 365 149 
Diastolic 
BP 
48.0 119.0 52.0 110.0 74±0.5 77.12±1.1 365 149 
sFlt-1 
(pg/ml) 
11.0 581.0 11.0 265.0 117.3±2.7 89.5±2.7 365 149 
Neopterin 
(nM) 
0.0 210.8 0.0 210.8 22.9±1.8 22.9±1.8 92 46 
7,8 NP 
(nM) 




16.58 624.6 16.58 624.6 94.4±9.1 94.4±9.1 92 46 
Statin 
usage 
- - - - - - 315 109 
Tobacco 
usage 
- - - - - - 189 54 
Diabetes 
II 
- - - - - - 60 22 
Table 3.1.1 General summary of CDCS patients. Clinical parameters were assessed at 
baseline for patients of the CDCS cohort. The data presented shows mean±SEM. 
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The descriptive statistics of the CDCS cohort indicates that levels of sFlt-1 (in 514 
patients) ranged from 11 pg/ml to 581 pg/ml, with a mean of 117.3±2.7 pg/ml and a standard 
deviation of 62 pg/ml. Levels of sFlt-1 did not differ significantly between males (117.5±3.3 
pg/ml) or females (116.5±4.8 pg/ml). Levels of total neopterin, in 138 of the CDCS patients, 
ranged between 16.58 nM and 624.6 nM, with a mean of 94.4±9.1 nM and a standard deviation 
of 107.08 nM. Unlike sFlt-1 total neopterin was significantly higher in females (134.2±23.9 
nM) than males (74.6±5.7 nM). Neopterin levels (22.9±1.8 nM) contributed less to the overall 
total neopterin count than 7,8NP levels (66.2±7.8 nM). Of the two pterins only 7,8 NP levels 
were significantly different between males (53.2±5.2 nM) and females (93.1±20.9 nM). Mean 
neopterin levels were 26±4.7 nM and 21.3±1.6 nM for females and males respectively. 
 
3.1.1 Statistical Power of CDCS in comparison with Matsumoto et al., 2013. 
Statistical power is the strength/magnitude of the study. The more power the less likely 
the chances of making an error in accepting the null hypothesis, otherwise referred to as a type 
two error. In this case the sFlt-1 data, obtained from the CDCS cohort plasma by ELISA assay, 
was compared to the data obtained in a similar experiment by Matsumoto et al. (2013). This 
tells us, that although different values were obtained by Matsumoto et al. (2013), the value of 
the data generated in this thesis is significant. 
Fig 3.1.1. Distribution Schematic. Indicating distribution of the data on CDCS cohort 
(Grey) and Matsumoto Cohort (Green) sFlt-1 levels.   
 
CDCS average H0= 117.2607 Matsumoto’s average (Ha)=298.1 
α1= -.05 








Calculation of statistical power for CDCS: 




      1.96 = 
(𝛼2−117.2607)
61.9/√514




)) + 117.2607   α2 =(1.96 (
61.9
√514
)) + 117.2607 
α1 = 111.9093278       α2 = 122.6120722 
Probability of (111.9093278<𝛼<1226127022) In terms of pg/ml 
Conversion to percentage probability: 
111.9093278−298.1
61.9/√514




-68.19441848< α <-64.2744185                  
Power (β) = 0.94251729 = 94% Probability of correctly rejecting the null hypothesis when it is 
false. 
As can be observed from the calculation above, the dataset has a 94.25% likelihood of 
correctly rejecting the null hypothesis (that sFlt-1 is not an independent predictor of all-cause 


















3.1.2 Relationship between CVD variables and biomarkers 
Multiple univariate general linear models were used to assess the hypothesis that 
variables commonly associated with CVD exhibit a significant relationship to the biomarkers 
sFlt-1, neopterin, 7,8NP and total neopterin. 
 
 Dependent Variable:   sFLT1   
Source 
Type III Sum 





6 24166.079 6.958 .000 
Intercept 53123.711  1 53123.711 15.297 .000 
BNP 25584.641 36.80±2.90 1 25584.641 7.367 .007 
Drinks/Week 58847.323 9.50±1.50 1 58847.323 16.945 .000 
Diastolic BP 46227.330 73.23±0.85 1 46227.330 13.311 .000 
Heart rate 15606.492 465.66±0.79 1 15606.492 4.494 .035 
BMI 3746.073 28.09±0.30 1 3746.073 1.079 .300 
Gender 2715.418  1 2715.418 .782 .377 
Error 1121756.388  323 3472.930   
Total 6007959.000  330    
Corrected Total 1266752.864  329    
Table 3.1.2. Commonly associated variables expressed in a general linear model with sFlt-
1 as the dependent variable. Data is expressed as mean ± SEM. Covariates were assessed for 
their association to sFlt-1 expressed as a linear model. All measures were taken post-recovery 
from an initial CV event. A type III sum of squares method (equivalent to Yates' weighted-
squares-of-means technique) was employed to deal with the unbalanced models. 
 
Aside from gender and BMI all covariates BNP, drinks/week, diastolic blood pressure 
and heart rate were shown to be significantly associated (P<0.05) to the linear regression model 












  Dependent variable: Total neopterin 
Source 
Type III Sum 





6 12640.692 2.021 .074 
Intercept 7215.664  1 7215.664 1.154 .286 
BNP 1796.485 31.63±2.90 1 1796.485 .287 .594 
Drinks/Week 62012.016 9.03±1.12 1 62012.016 9.916 .002 
Diastolic BP 428.536 77.12±1.12 1 428.536 .069 .794 
HR 3692.188 66.27±0.97 1 3692.188 .590 .445 
BMI .760 27.35±0.40 1 .760 .000 .991 
Gender 26708.697  1 26708.697 4.271 .042 
Error 437747.885  70 6253.541   
Total 981549.961  77    
Corrected Total 513592.037  76    
Table 3.1.3. Commonly associated variables expressed in a general linear model with both 
neopterin and 7,8NP combined as the dependent variable. Data is expressed as mean± 
SEM. Covariates were assessed for their association to total neopterin expressed as a linear 
model.  
 
Unlike the general linear model of sFlt-1, aside from gender and alcohol consumption, 
none of the covariates were significantly associated with total neopterin (Table 3.1.3).  
 
From this model there is no evidence provided to support the hypothesis that levels of 
BNP, diastolic blood pressure, heart rate or BMI are associated with total neopterin levels in 
patients after ACS. On the other hand alcohol consumption, like with sFlt-1, was a significant 
(P<0.05) covariate and may therefore be associated with pathways responsible for total 















Dependent Variable: Neopterin 
Source 
Type III Sum 





6 435.926 2.127 .061 
Intercept 842.859  1 842.859 4.112 .046 
BNP 1086.871 31.63±2.90 1 1086.871 5.302 .024 
Drinks/Week 351.248 9.03±1.12 1 351.248 1.714 .195 
Diastolic BP 7.666 77.12±1.12 1 7.666 .037 .847 
Heart rate 12.127 66.27±0.97 1 12.127 .059 .809 
BMI 1003.512 27.35±0.40 1 1003.512 4.896 .030 
Gender 14.016  1 14.016 .068 .794 
Error 14758.277  72 204.976   
Total 53387.304  79    
Corrected Total 17373.835  78    
Table 3.1.4. Commonly associated variables expressed in a general linear model with 
neopterin as the dependent variable. Data is expressed as mean± SEM. Covariates were 
assessed for their association to neopterin expressed as a linear model.  
 
BNP, and BMI were significantly associated (P<0.05) with neopterin, indicating that 
these variables are potentially associated to levels of neopterin post CVD event. However, no 
other covariates in the model exhibited any significant association (P<0.05) (Table 3.1.4). 
Notably, the same significant relationship was not observed, between neopterin and alcohol 
consumption, that was observed between alcohol consumption and both sFlt-1 and total 















 Dependent Variable:   7,8 NP   
Source 
Type III Sum 





6 11586.426 1.957 .084 
Intercept 3037.864  1 3037.864 .513 .476 
BNP 55.537 31.63±2.90 1 55.537 .009 .923 
Drinks/Week 51904.133 9.03±1.12 1 51904.133 8.766 .004 
Diastolic BP 498.291 77.12±1.12 1 498.291 .084 .773 
HR 3900.932 66.27±0.97 1 3900.932 .659 .420 
BMI 771.396 27.35±0.40 1 771.396 .130 .719 
Gender 25052.786  1 25052.786 4.231 .043 
Error 408555.772  69 5921.098   
Total 724441.464  76    
Corrected Total 478074.326  75    
Table 3.1.5. Commonly associated variables expressed in a general linear model with 7,8 
NP as the dependent variable. Data is expressed as mean± SEM. Covariates were assessed 
for their association to 7,8NP expressed as a linear model.  
 
Much like total neopterin, both alcohol consumption and gender were shown to be 
significantly associated to 7,8NP (P<0.05). All other included covariates were not significantly 


















3.1.3 Direct correlations between Biomarkers and significant variables 
A multiple comparison bivariate analysis was used to assess the relationship between 
significant variables in the general linear models and the biomarkers. In the same analysis the 





Neopterin 7,8NP BNP 
sFLT1 Pearson 
Correlation 
1 .178** .042 -.088 -.098 .098* 
Sig. (2-tailed)  .001 .618 .304 .260 .027 





.178** 1 .098 .287** .267* -.081 
Sig. (2-tailed) .001  .364 .007 .013 .125 
N 362 362 88 86 85 362 
Neopterin Pearson 
Correlation 
.042 .098 1 .372** .141 .070 
Sig. (2-tailed) .618 .364  .000 .102 .405 





-.088 .287** .372** 1 .972** -.012 
Sig. (2-tailed) .304 .007 .000  .000 .889 
N 138 86 136 138 135 138 
7,8NP Pearson 
Correlation 
-.098 .267* .141 .972** 1 -.024 
Sig. (2-tailed) .260 .013 .102 .000  .782 
N 135 85 135 135 135 135 
BNP Pearson 
Correlation 
.098* -.081 .070 -.012 -.024 1 
Sig. (2-tailed) .027 .125 .405 .889 .782  
N 514 362 144 138 135 514 
Table 3.1.6. Correlations observed between significant factors. Analysis of correlations 
between biomarkers sFlt-1, neopterin, 7,8NP, Total neopterin, BNP and the commonly 
associated factor drinks per week. **: the correlation is significant at the P<0.01 level. *: the 
correlation is significant at the P<0.05 level. 
 
From the direct correlations shown in Table 3.1.6 a strong positive correlation (P<0.01) 
can be observed for alcohol consumed per week with sFlt-1 and total neopterin. A slightly 
weaker positive correlation can also be observed between levels of 7,8NP and alcohol 
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consumption. However, no correlation could be derived from alcohol consumed per week with 
neopterin or BNP. 
 
sFlt-1 was also shown to exhibit no significant correlation to neopterin 7,8NP or total 
neopterin levels. However a significant correlation was observed between sFlt-1 and both 































3.1.4 Survival analysis of CDCS patients 
In order to determine the predictive and prognostic capabilities of the biomarkers 
Kaplan-Meier and Cox proportional regression analyses were performed to evaluate the 
incidence of death and TCVE (Total cardiovascular events) in the follow up period post-
cardiovascular event. Using information derived from the general linear models and direct 
correlation statistics, significant variables were identified to be included in the Cox 
proportional regression models. Of the 138 patients analysed for total neopterin, neopterin and 
7,8 NP, from the 514 patient CDCS cohort, 32 patients died, 22 of which died from CVD and 
88 patients developed TCVE. Of the 514 patients analysed for sFlt-1, 148 patients died, 97 of 
which died from CVD, and 358 patients developed TCVE.  
 
Total neopterin survival analysis 
 
Fig 3.1.2. Total neopterin ACD Kaplan-Meier analysis. Cumulative survival of ACD in 
CDCS patients with above median (2, green) and below (1, blue) total neopterin levels over a 




 Chi-Square df Sig. 
Log Rank  7.717 1 .005 
Breslow  9.565 1 .002 
Tarone-Ware 8.896 1 .003 
Table 3.1.7. Test for equality of survival distributions for the different levels of total 
neopterin. Log Rank analysis indicates difference in equality of survival functions when all 
time points are weighted the same. Breslow analysis indicates difference in equality of survival 
functions when all time points are weighted by the number of cases at risk at each time point. 
Tarone-Ware analysis indicates difference in equality of survival functions when all time points 
are weighted by the square root of the number of cases at risk at each time point. 
 
 
 Coefficient SE Sig. 
Hazard 
Ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
Total neopterin 1.972 .695 .005 7.187 1.839 28.080 
BNP .637 .655 .331 1.891 .524 6.829 
Age at baseline .295 .102 .004 1.343 1.100 1.641 
Drinks Per Week 1.179 .576 .041 3.250 1.052 10.041 
Table 3.1.8. Cox proportional hazards model for ACD vs total neopterin, BNP, age at 
baseline and drinks per week. A model of time to ACD based on the value of the covariates 
BNP, age at baseline, drinks per week and Total neopterin. Median separation points being 
94.4 nM, 34.1 pg/ml, 9.0 drinks and 68.8 years for Total neopterin, BNP, drinks per week and 
age at baseline respectively. 
 
When patients were divided into two groups, according to the median value for total 
neopterin (94.4 nM), a significant association was exhibited between patients with an above 
median level of total neopterin and ACD (all cause death), with reduced survival observable in 
patients with above median levels (Fig. 3.1.2). Furthermore, overall tests for the equality of 
survival scores at different time points showed that all time points were significant (p< 0.05), 
establishing that there is a statistically significant difference between patient’s survival with 
above and below median levels of total neopterin across the 5.4 year follow up period (Table. 
3.1.7). 
 Further analysis of its prognostic use, in determining ACD using a Cox proportional 
analysis, revealed that higher than median total neopterin, higher alcohol consumption and a 
higher than median age were all associated with adverse outcomes. With the assumption that 
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the covariates have an effect on the hazard function, total neopterin, age at baseline and alcohol 
consumption were all shown to be significant. As a result the hazard ratios of 7.187, 1.343 and 
3.250, for total neopterin, age at baseline and alcohol consumption respectively, can be deemed 
as significant with respect to matching the Cox proportional hazard model (Table 3.1.8). This 
result, along with the Kaplan-Meier analysis, indicates that 7,8NP is an independent predictor 
of survival in patients post-CVD event. However, the commonly used ventricular wall stress 
biomarker BNP, which is a well-established prognostic marker in CVD, was not significant.  
 
Fig 3.1.3. Total neopterin TCVE Kaplan-Meier analysis. TCVE in CDCS patients with 
above (2, green) and below (1, blue) median total neopterin (94.4728 nM) levels over a 5.4 
year period. 1 and 2 censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  2.189 1 .139 
Breslow  2.185 1 .139 
Tarone-Ware 2.301 1 .129 




 Coefficient SE Sig. 
Hazard 
Ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
Total neopterin .242 .309 .432 1.274 .696 2.333 
BNP .095 .330 .773 1.100 .576 2.099 
Age at baseline .125 .056 .025 1.133 1.016 1.263 
Drinks per week .463 .299 .121 1.589 .885 2.854 
Table 3.1.10. Cox proportional hazards model for TCVE vs total neopterin, BNP, age at 
baseline and drinks per week. A model of time to TCVE based on the value of the covariates 
BNP, Age at baseline, drinks per week and total neopterin. Median separation points being 
94.4 nM, 34.1 pg/ml 9.0 drinks and 68.8 years for Total neopterin, BNP, drinks per week and 
age at baseline respectively. 
 
In contrast, to total neopterins prognostic utility in determining ACD, its potential 
predictive capabilities for determining TCVE were not supported by this dataset.  
 
Like the Kaplan-Meier analysis for ACD, TCVE were shown to occur early in the 
follow up period as well as being more frequent over the 5.4 year follow up period for patients 
with higher than median levels of total neopterin (Fig 3.1.3). However, overall tests of TCVE 
at different time points showed that at all time points the difference, between above and below 
median levels of total neopterin, was not- significant (p>0.05) (Table 3.1.9).  
  
 A univariate Cox proportional regression analysis of the dataset showed that, of the four 
variables BNP, total neopterin, age at baseline and drinks per week, only age at baseline was 
significantly associated with TCVE (p<0.05). Therefore, in the same model, total neopterin, 
alcohol consumption and BNP are not indicated as predictive markers with respect to TCVE 
in patients post CVD event (Table 3.1.10). This result, along with the insignificant Kaplan-
Meier analysis, suggests that, although total neopterin and alcohol consumption may be 






Fig 3.1.4. Total neopterin CVD death Kaplan-Meier analysis. CVD death in CDCS patients 
with above (2, green) and below (1, blue) median total neopterin (94.4728 nM) levels over a 
mean 5.4 year period. 1 and 2 censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  3.204 1 .073 
Breslow  3.012 1 .083 
Tarone-Ware 3.040 1 .081 










 Coefficient SE Sig. 
Hazard 
Ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
Total neopterin 1.110 .556 .046 3.034 1.020 9.027 
BNP .458 .570 .422 1.580 .517 4.833 
Age at baseline .190 .096 .048 1.210 1.002 1.461 
Drinks per week -.172 .523 .741 .842 .302 2.344 
Table 3.1.12. Cox proportional hazards model for CVD death vs total neopterin, BNP, 
age at baseline and alcohol consumption. A model of time to CVD death based on the 
value of the covariates BNP, Age at baseline, drinks per week and total neopterin. Median 
separation points being 94.4 nM, 34.1 pg/ml 9.0 drinks and 68.8 years for total neopterin, 
BNP, drinks per week and age at baseline respectively. 
 
Although a difference in CVD death, between patients with above and below median 
levels of total neopterin, was observed, over the 5.4 year follow up period, this difference was 
not significant (Fig 3.1.4.). Overall analysis of the survival curves indicates that, at any point 
in the survival analysis, the difference observed between the two groups was not significant 
(p>0.05) and therefore doesn’t suggest a positive relationship between higher levels of total 
neopterin and CVD death (Table 3.1.11). 
 
 Like the Cox proportional analysis of TCVE neither BNP nor drinks per week were 
significantly associated with CVD death. Although patients expressing higher than median 
levels of total neopterin were not indicated as significantly more at risk of CVD death by the 
Kaplan-Meier analysis, the Cox proportional regression provides a different outlook. In the 
same cox proportional regression analysis total neopterin and age at baseline are indicated as 
significant (P<0.05), with patients in the above median total neopterin group having a 3-fold 
higher risk of CVD death. Unlike total neopterin both BNP and alcohol consumption exhibited 
no significant relationship to CVD death in the 5.4 year follow up period (Table 3.1.12). 
Therefore, the significant association observed, between ACD and total neopterin, may be due 








Neopterin survival analysis 
 
Fig 3.1.5. Neopterin ACD Kaplan-Meier analysis. Cumulative survival of CDCS patients 
with above (2, green) and below (1, blue) median neopterin (22.8555 nM) levels over a 5.4 
year period. 1 and 2 censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  3.228 1 .072 
Breslow  3.707 1 .054 
Tarone-Ware 3.521 1 .061 










 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .609 .670 .363 1.839 .494 6.839 
Age at baseline .285 .108 .008 1.330 1.077 1.642 
Drinks per week 1.019 .550 .064 2.772 .943 8.148 
Neopterin 1.725 .697 .013 5.614 1.431 22.017 
Table 3.1.14. Cox proportional hazards model for ACD vs neopterin, BNP, age at baseline 
and drinks per week. A model of time to ACD based on the value of the covariates BNP, Age 
at baseline, drinks per week and neopterin. Median separation points being 22.9 nM, 9.0 drinks, 
34.1 pg/ml and 68.8 years for neopterin, drinks per week, BNP and age at baseline respectively. 
 
From the Kaplan-Meier analysis (Fig. 3.1.5), for neopterin vs ACD, no significant 
difference can be identified at any time point, between levels above and below the median, for 
neopterin in patients after recovery from a CVD event (Table 3.1.13).   
 
Neopterin, expressed as a covariate alongside age at baseline, alcohol consumption and 
BNP, in a univariate Cox proportional regression model, however shows that neopterin is a 
significant predictor of death, with patients in the above average neopterin group experiencing 
a 5.6 fold greater risk of ACD post CVD event. However, unlike neopterin, the model identifies 
BNP and drinks per week as non-significant (P>0.05) predictors of ACD (Table 3.1.14). 
 
 Therefore, neopterins prognostic utility is supported. As analysis shows a significant 
difference in ACD for above and below median levels and significant prognostic ability in 




Fig 3.1.6. Neopterin TCVE Kaplan-Meier analysis. TCVE in CDCS patients with above 
(>22.9 nM, 2, green) and below (<22.9 nM, 1, blue) median neopterin (22.86 nM) levels over 
a 5.4 year period. 1 and 2 censored represents patients who were lost to follow-up 
 
 Chi-Square df Sig. 
Log Rank  .338 1 .561 
Breslow  .391 1 .532 
Tarone-Ware .400 1 .527 











 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .162 .325 .618 1.176 .622 2.225 
Drinks per week .525 .302 .082 1.690 .936 3.052 
Age at baseline .125 .056 .025 1.134 1.016 1.265 
Neopterin .169 .312 .588 1.184 .643 2.181 
Table 3.1.16. Cox proportional hazards model for TCVE vs neopterin, drinks per week, 
BNP and age at baseline. A model of time to TCVE based on the value of the covariates BNP, 
Age at baseline, Drinks per week and Neopterin. Median separation points being 22.9 nM, 9.0 
drinks, 34.1 pg/ml and 68.8 years for neopterin, drinks per week, BNP and age at baseline 
respectively. 
 
Neopterins incapacity to predict TCVE is highlighted in the Kaplan-Meier analysis 
above (Fig. 3.1.6.). Cardiovascular events, occurring in patients with above and below median 
levels of neopterin, largely follow the same trend with an initial period of frequent CV events 
over the first two years, followed by a less frequent occurrence in the below median group  over 
the next 3 years. No significant association was identified between levels of neopterin and 
TCVE at any period over 5.4 years (Table 3.1.15). 
 
 The biomarker utility of neopterin in predicting TCVE is further discredited by analysis 
of neopterin alongside BNP, drinks per week and age at baseline in a univariate cox 
proportional hazards model (Table 3.1.16). Much like the model of ACD, age at baseline 
significantly predicts TCVE. Neopterin however, does not show significant utility in predicting 







Fig 3.1.7. Neopterin CVD death Kaplan-Meier analysis. CVD death in CDCS patients with 
above (>22.9 nM, 2, green) and below (<22.9 nM, 1, blue) median neopterin (22.8555 nM) 
levels over a mean 5.4 year period. 1 and 2 censored represents patients who were lost to 
follow-up. 
 
 Chi-Square df Sig. 
Log Rank  .472 1 .492 
Breslow  .541 1 .462 
Tarone-Ware .491 1 .484 










 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .700 .574 .223 2.013 .653 6.204 
Drinks per week -.262 .513 .609 .769 .281 2.103 
Age at baseline .153 .095 .106 1.165 .968 1.404 
Neopterin .203 .518 .695 1.225 .444 3.384 
Table 3.1.18. Cox proportional hazards model for CVD death vs neopterin, BNP, drinks 
per week and age at baseline. A model of time to CVD death based on the value of the 
covariates BNP, Age at baseline, drinks per week and neopterin. Median separation points 
being 22.9 nM, 9.0 drinks, 34.1 pg/ml and 68.8 years for neopterin, drinks per week, BNP and 
age at baseline respectively. 
 
Higher levels of neopterin did not result in any observable difference in the incidence 
of CVD death. As can be observed in the Kaplan Meier analysis incidence of CVD death 
remains relatively equal, in patients with above and below median levels of neopterin, 
throughout the 5.4 year follow up period (Fig 3.1.7).  
 
 Overall analysis of the survival curves indicates that, at any point in the survival 
analysis, the difference observed between the two groups was not significant (p>0.05) and 
therefore doesn’t suggest a positive relationship between higher levels of neopterin and CVD 
death (Table 3.1.17). 
 
 The lack of an observable relationship between neopterin and CVD death is further 
identified by the Cox proportional analysis. No significant increase in prevalence of CVD death 
was observed in any of the variables included in the analysis (Table 3.1.18). The dataset 
therefore does not support the use of neopterin alongside age at baseline, alcohol consumption 










7,8NP survival analysis 
 
Fig 3.1.8. 7,8 NP ACD Kaplan-Meier analysis. Cumulative survival of CDCS patients with 
above (2, green) and below (1, blue) median 7,8 NP (66.2224 nM) levels over a 5.4 year period. 
1 and 2 censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  5.343 1 .021 
Breslow  6.335 1 .012 
Tarone-Ware 6.071 1 .014 










 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .889 .636 .162 2.434 .700 8.458 
Drinks per week .970 .560 .083 2.638 .880 7.906 
Age at baseline .251 .103 .015 1.285 1.050 1.573 
7,8NP 1.361 .619 .028 3.899 1.159 13.124 
Table 3.1.20. Cox proportional hazards model for ACD vs 7,8 NP, drinks per week, BNP 
and age at baseline. A model of time to ACD based on the value of the covariates BNP, drinks 
per week, Age at baseline and 7,8NP. Median separation points being 66.2 nM, 9.0 drinks, 34.1 
pg/ml and 68.8 years for 7,8NP, drinks per week, BNP and age at baseline respectively. 
 
Over the 5.4 year follow up period patients, with 7,8NP levels above the median value 
of 66.2 nM, experienced a significantly higher rate of mortality. As identified, by the Kaplan- 
Meier analysis, patients in the higher plasma 7,8NP group were significantly more likely to die 
within the follow up period (Fig. 3.1.8) highlighting its potential prognostic utility in patients 
after recovery from a CV event. This is further supported by the Log-rank, Breslow and Tarone-
Ware analyses, providing evidence that differences, between above and below median levels 
of 7,8 NP, in the incidence of ACD, are significant (p<0.05) across the 5.4 year period (Table. 
3.1.19). 
 
Of the four covariates BNP, age at baseline, alcohol consumption and 7,8NP only 
7,8NP and age at baseline were significantly associated with ACD (Table 3.1.20), with hazard 
ratios of 3.899 and 1.285 respectively. Therefore 7,8NP shows prognostic promise, for its 
capability to predict ACD, in patients post-CV event in conjunction with the covariate age at 
baseline. On the other hand, BNP and alcohol consumption did not significantly fit the Cox 








Fig 3.1.9. 7,8 NP TCVE Kaplan-Meier analysis. TCVE in CDCS patients with above (2, 
green) and below (1, blue) median 7,8 NP (66.2 nM) levels over a 5.4 year period. 1 and 2 
censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  2.027 1 .155 
Breslow  1.692 1 .193 
Tarone-Ware 1.951 1 .162 









 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .190 .328 .563 1.209 .636 2.297 
Drinks per week .485 .298 .103 1.625 .907 2.912 
Age at baseline .110 .055 .047 1.116 1.001 1.244 
7,8 NP .188 .302 .533 1.207 .667 2.184 
Table 3.1.22. Cox proportional hazards model for TCVE vs 7,8 NP, drinks per week, BNP 
and age at baseline. A model of time to TCVE based on the value of the covariates BNP, 
drinks per week, Age at baseline and 7,8NP. Median separation points being 66.2 nM, 9.0 
drinks, 34.1 pg/ml and 68.8 years for 7,8NP, drinks per week, BNP and age at baseline 
respectively. 
 
Although a difference in TCVE was observed, between patients with above and below 
median levels in a Kaplan-Meier analysis, 7,8NP was not shown to be significantly associated 
with TCVE (Fig. 3.1.9.). Across the 5.4 year period no significant association was made 
between TCVE and 7,8NP as highlighted by the log rank, Breslow and Tarone-Ware analyses 
(Table 3.1.21). Therefore, its predictive capabilities in determining incidence of CV events are 
not supported. 
 
When associated with BNP, alcohol consumption and age at baseline in the same Cox 
proportional regression model only age at baseline was shown to be significant (P<0.05) with 
a hazard ratio of 1.116. Both of the markers of interest, BNP and 7,8NP and the alcohol 
consumption covariate, were not shown to significantly fit the model. Therefore, in the same 
model, 7,8NP, alcohol consumption and BNP are not indicated as predictive markers with 
respect to TCVE in patients post recovery from a CVD event (Table 3.1.22). This result, along 
with the insignificant Kaplan-Meier analysis, suggests that although 7,8NP, like total 
neopterin, may be a significant prognostic marker of ACD, it is not significantly associated 





Fig 3.1.10. 7,8 NP CVD death Kaplan-Meier analysis. CVD death in CDCS patients with 
above (2, green) and below (1, blue) median 7,8 NP (66.2224 nM) levels over a mean 5.4  year 
period. 1 and 2 censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  3.192 1 .074 
Breslow  3.090 1 .079 
Tarone-Ware 3.088 1 .079 











 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .684 .556 .219 1.981 .666 5.889 
Drinks per week -.213 .520 .683 .808 .292 2.241 
Age at baseline .167 .095 .078 1.182 .981 1.423 
Dihydroneopterin 1.162 .540 .032 3.197 1.108 9.220 
Table 3.1.24. Cox proportional hazards model for CVD death vs 7,8 NP, drinks per week, 
BNP and age at baseline. A model of time to CVD death based on the value of the covariates 
BNP, drinks per week, Age at baseline and 7,8NP. Median separation points being 66.2 nM, 
9.0 drinks, 34.1 pg/ml and 68.8 years for 7,8NP, drinks per week, BNP and age at baseline 
respectively. 
 
Similar results were observed in the survival analysis of 7,8NPs relationship to CVD 
death that were observed in total neopterins relationship to CVD death.  Although a difference 
in CVD death, between patients with above and below median levels of total neopterin, was 
observed, over the 5.4 year follow up period (Fig 3.1.10), this difference was not found to be 
significant at any point in the analysis (P>0.05) (Table 3.1.23). Therefore, its predictive 
capability in determining incidence of CVD death was not supported by this dataset. 
 
 No significant predictive capabilities were identified for BNP or alcohol consumption 
in determining incidence of CVD death (P>0.05). Age at baseline and 7,8NP however, did 
indicate significant predictive capabilities.  From the Cox proportional regression model it 
can be observed that patients with an above median level of 7,8NP have a 3.2 fold greater 
chance of death from CVD over the 5.4 year follow up period. Furthermore this hazard ratio, 
as well as the hazard ratio for age at baseline, was significant (P<0.05) (Table 3.1.24). 
Therefore the capabilities of 7,8NP alongside age at baseline, in predicting CVD death, are 










sFlt-1 survival analysis 
 
Fig 3.1.11. sFlt-1 ACD Kaplan-Meier analysis. Cumulative survival of CDCS patients with 
above (green) and below (blue) median sFlt-1 (117.2607 pg/ml) levels over a 4000 day (10 
year) period. 1 and 2 censored represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  15.738 1 .000 
Breslow  14.949 1 .000 
Tarone-Ware 15.414 1 .000 










 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .400 .231 .084 1.492 .948 2.348 
Drinks per week .224 .208 .282 1.251 .832 1.883 
Age at baseline .325 .046 .000 1.384 1.265 1.515 
sFlt-1 .688 .229 .003 1.990 1.270 3.120 
Table 3.1.26. Cox proportional hazards model for ACD vs sFlt-1, drinks per week, BNP 
and age at baseline. A model of time to ACD based on the value of the covariates BNP, drinks 
per week, Age at baseline and sFlt-1. Median separation points being 117.26 pg/ml, 9.0 drinks,  
34.1 pg/ml and 68.8 years for sFlt-1, drinks per week, BNP and age at baseline respectively. 
 
It is observable from the Kaplan-Meier analysis of ACD that patients with above 
median levels of sFlt-1 have a drastic increase in ACD compared to patients with below median 
sFlt-1 levels (Fig 3.1.11). Across the 10 year period a highly significant association was made 
between ACD and sFlt-1, at all time points in the analysis, as highlighted by the log rank, 
Breslow and Tarone-Ware analyses (P<0.01) (Table. 3.1.25). sFlt-1’s prognostic capacity in 
determining all cause death post-recovery from a CVD event, is therefore highly supported by 
this dataset. 
 
 The prognostic capacity of sFlt-1 is further supported by its significant prognostic 
utility in conjunction age at baseline (Fig 3.1.25). Age at baseline and sFlt-1 were all shown to 
be significantly associated with ACD (P<0.01) with hazard ratios of 1.38 and 2.00 respectively 
indicating that patients with above median levels of sFlt-1 were twice as likely to die over the 
10 year follow up period (Table 3.1.26). The same cannot be said for BNP and drinks per week, 
which were shown to be insignificant (P>0.05), with respect to the Cox proportional regression 
for ACD. Therefore, the use of sFlt-1, alone or alongside age at baseline, for determining 





Fig 3.1.12. sFlt-1 TCVE Kaplan-Meier analysis. TCVE in CDCS patients with above (green) 
and below (blue) median sFlt-1 (117.2607 pg/ml) levels over a 10 year period. 1 and 2 censored 
represents patients who were lost to follow-up. 
 
 Chi-Square df Sig. 
Log Rank  2.523 1 .112 
Breslow  .670 1 .413 
Tarone-Ware 1.470 1 .225 













 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard Ratio 
Lower Upper 
BNP .163 .141 .247 1.177 .893 1.552 
Drinks per week .150 .130 .250 1.161 .900 1.498 
Age at baseline .107 .025 .000 1.113 1.059 1.170 
sFlt-1 .230 .131 .078 1.259 .975 1.627 
Table 3.1.28. Cox proportional hazards model for TCVE vs sFlt-1, drinks per week, BNP 
and age at baseline. A model of time to TCVE based on the value of the covariates BNP, 
drinks per week, Age at baseline and sFlt-1. Median separation points being 117.26 pg/ml, 9.0 
drinks, 34.1 pg/ml and 68.8 years for sFlt-1, drinks per week, BNP and age at baseline 
respectively. 
 
Over the initial 3 year follow up period approximately 60 percent of patients with both 
above and below median levels of sFlt-1 experienced CV events at almost the same rate. 
However, after this initial 3 year period, patients with a higher than median level of sFlt-1 
experienced a higher incidence of CV events (Fig 3.1.12). Although patients expressing higher 
levels of sFlt-1 did eventually experience more CV events this was not shown to be significant 
in comparison to below median levels across the 10 year follow up period (Table 3.1.27). 
 
When sFlt-1s utility in determining TCVE was analysed in a Cox proportional 
regression model, alongside BNP, alcohol consumption and age at baseline, its predictive 
utility trended towards significance (p=0.078) and BNP and alcohol consumption, were shown 
to be insignificant (P>0.05) (Table 3.1.28). Age at baseline however was shown to be a highly 













Fig 3.1.13. sFlt-1 CVD death Kaplan-Meier analysis. CVD death in CDCS patients with 
above (green) and below (blue) median sFlt-1 (117.2607 pg/ml) levels over a 10 year period. 
1 and 2 censored represents patients who dropped out for reasons unrelated to the study or 
were lost track of. 
 
 Chi-Square df Sig. 
Log Rank  10.948 1 .001 
Breslow  11.704 1 .001 
Tarone-Ware 11.573 1 .001 











 Coefficient SE Sig. 
Hazard 
ratio 
95.0% CI for 
Hazard ratio 
Lower Upper 
BNP .743 .320 .020 2.102 1.121 3.939 
Drinks per week .267 .275 .332 1.305 .762 2.236 
Age at baseline 1.838 .373 .000 6.286 3.024 13.065 
sFlt-1 .607 .308 .049 1.835 1.003 3.356 
Table 3.1.30. Cox proportional hazards model for CVD death vs sFlt-1, BNP, drinks per 
week and age at baseline. A model of time to TCVE based on the value of the covariates BNP, 
drinks per week, Age at baseline and sFlt-1. Median separation points being 117.26 pg/ml, 9.0 
drinks, 34.1 pg/ml and 68.8 years for sFlt-1, drinks per week, BNP and age at baseline 
respectively. 
 
Incidence of CVD death was found significantly more in patients with above, compared 
to below, median levels of sFlt-1 (Fig 3.1.13.). The highly significant association between 
above median levels of sFlt-1 and ACD can therefore be attributed to CVD death. This result 
is further highlighted by the Log rank, Breslow and Tarone-Ware analyses of the Kaplan-Meier 
trend. All three analyses show that sFlt-1 is significantly associated to CVD death at any time 
over the 10 year follow up period (Table 3.1.29). 
 
 
sFlt-1 was also shown, in the Cox proportional regression model, to have significant 
predictive utility in determining the risk of CVD death. Furthermore all of the other included 
covariates, with the exception of alcohol consumption, showed significant utility for 
determining the risk of CVD death (Table 3.1.30). Overall the results of The Kaplan Meier 
analysis and Cox proportional regression model provide compounding support for the 
predictive utility of sFlt-1. Indicating that when analysed alone, and in combination with the 
other significant covariates, sFlt-1 has a strong association with CVD death in patients post 









3.2 Carotid endarterectomy cohort  
 
Carotid endarterectomy plasma and plaque were analysed to determine the levels of 
pterins and sFlt-1, in patients with known atherosclerotic lesions, and to assess the capability 
of the plaque itself to produce these biomarkers. Plaque and blood samples from the 
endarterectomy cohort were obtained immediately prior to the carotid endarterectomy 
procedure at Christchurch Hospital, by Prof Justin Roake and associates of the Vascular 
Surgery Department (Refer to table 6.1 in Appendix for patient’s plaque summary and 6.2 for 
individual patient plasma summary). Extracted plasma was analysed for sFlt-1, neopterin, 
7,8NP and total neopterin. Atherosclerotic plaques were removed and immediately cultured, 
prior to assessment, or stored at -80 ◦C (refer to Methods section 2.2). Control patient plasma 
was donated by the Christchurch Heart Institute (Control patient plasma summarised in table 
6.3 in appendix). 
 







6.18 57.03 25.76±2.18 25.17±2.95 27.09±2.74 8 18 
7,8NP 
(nM) 




23.25 81.58 50.30±3.01 50.41±4.21 50.05±2.86 8 18 
sFlt-1 
(pg/ml) 
2.00 20453.00 8932.11±1121.83 9154.05±1424.68 8405.00±1823.17 8 19 












3.2.1 Plasma analysis 
 The plasma from the endarterectomy cohort was compared to age and gender matched 
control samples. The process was primarily carried out to confirm whether patients with carotid 
atherosclerotic plaque carried higher concentrations of the biomarkers than healthy individuals. 
Also, using this method, levels observed between genders or age groups were compared to 
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Fig 3.2.1. sFLT-1 measured in endarterectomy plasma versus age and gender matched 
control plasma. Error bars exhibit mean+SEM. Male N=19 (***=p<0.001), Female N=8 
(**=p<0.01). Tukey post-hoc indicates levels of sFLT-1 are not significantly different across 
age groups or between gender groups (p>0.05). 
 
Analysis of the endarterectomy patient plasma indicated a significant difference in sFlt-
1 levels between healthy controls (n=24, Male=240±71 pg/ml, Female=355±52 pg/ml) and 
patients with advanced atherosclerotic lesions in the carotid artery (n=27, Male=1945±1425 
pg/ml, Female=8404±1823 pg/ml) (Fig 3.2.1). No significant difference in sFlt-1 levels were 
observed between the genders or patients of different age groups (p>0.05), indicating that 
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Fig 3.2.2. Neopterin measured in endarterectomy plasma vs age and gender matched 
control plasma. Error bars exhibit mean+SEM. Male N=18 (*= p<0.05), Female N=8 
(**=p<0.01). Turkey post-hoc indicates levels of neopterin are not significantly different 
across age groups or between gender groups (p>0.05). 
 
 
Levels of neopterin, measured in the endarterectomy patient cohort (n=26, 
Male=23.9±3.1 nM, Female=27.1±2.7nM) were significantly higher than those measured in 
age and gender matched controls (n=27, Male=12.8±1.4 nM, Female=15.5±3.8 nM) (Fig. 
3.2.2), indicating that the elevated levels of neopterin were not attributed to either the gender 



































































 Fig 3.2.3. 7,8NP measured in endarterectomy plasma vs age and gender matched control 
plasma. Error bars display Mean+SEM. Male N=18 (p>0.05), Female N=8 (*=p<0.05). Tukey 
post-hoc analysis indicates a significant difference between the gender group controls 
(P<0.05). 
 
 Significantly higher Levels of 7,8NP were observed in females with advanced 
atherosclerotic lesions (23±2.6 nM) than in healthy control females (12±3.5 nM). Suggesting 
that females with advanced carotid atherosclerotic lesions experience higher levels of 
macrophage activation (Fig. 3.2.3).  
 
 Levels of 7,8NP measured in the male endarterectomy group (24±3.0 nM) were 
insignificant when compared to the male healthy control group (21.7±3.0 nM). Furthermore, 
there was a significant difference between the male and female healthy control levels, 
indicating that the male healthy controls had higher levels of 7,8 NP compared to females, 









































































Fig 3.2.4. Total neopterin measured in endarterectomy plasma vs age and gender 
matched control plasma. Error bars display Mean+SEM. Male n=18 (p<0.05), Female n=8 
(p<0.05). Tukey post-hoc analysis indicates no significant difference between the gender group 
controls (p<0.05). 
 
Levels of total neopterin were significantly elevated for both males (48±3.0) and 
females (50±3.0 nM) in comparison to healthy age and gender matched controls 
(Female=27.5±6.5 nM, Males=34.5±3.5 nM) (Fig 3.2.4). The elevated levels of neopterin were 
not attributed to either the gender or the age of the patients, as the difference between the 











As levels of all the pterins and sFlt-1 were elevated, assesments were made to identify 
a possible correlation between the markers. In order to assess the possible association between 
levels of sFlt-1 and the pterins, in the plasma of the endarterectomy patients, a bivariate analysis 
was used.  
Fig 3.2.5. Bivariate analysis of sFlt-1 VS 7,8NP in endarterectomy patient plasma.  n=27 
sFlt-1, n=26 7,8NP, R2=0.323, p=0.002, 95% Mean confidence intervals. 
 
A statistically significant (p<0.01) positive correlation was observed between sFlt-1 
and 7,8NP (Fig 3.2.5), indicating a potential association between the two markers. The 
correlation model accounts for 32.3% of the dataset (R2=0.323), suggesting that much of the 
variation in the data isn’t explained by the relationship. 
 
The same positive relationship between sFlt-1 and 7,8NP was not observed in the 
healthy control group plasma (p>0.436, R2=0.029). 
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 Fig 3.2.6. Bivariate analysis of sFlt-1 VS neopterin in endarterectomy patient plasma. 
n=27 sFlt-1, n=26 neopterin, R2=0.027, p=0.424, 95% Mean confidence intervals. 
 
Unlike 7,8NP, neopterin levels do not share any significant positive relationship 
(p>0.05) with levels of sFlt-1 in endarterectomy patient plasma (Fig 3.2.6). 
  
As the model only accounts for 2.7% of the dataset variation, neopterin doesn’t 
indicate a predictive capacity in determining sFlt-1 levels or vice versa. Even less of a 
relationship was observed, between levels of sFlt-1 and neopterin, in the healthy patient 












Fig 3.2.7. Bivariate analysis of sFlt-1 VS total neopterin in endarterectomy patient 
plasma. n=27 sFlt-1, n=26 total neopterin, R2=0.267, p=0.007, 95% Mean confidence 
intervals. 
 
A significant (p<0.01) relationship was observed, between levels of sFlt-1 and levels 
of total neopterin, in plasma from patients in the endarterectomy cohort (Fig 3.2.7). With the 
model accounting for 26.7% of the dataset (R2=0.267), much of the variation is unexplained. 
  
There was no significant correlation, between sFlt-1 and total neopterin in the healthy 











3.2.3 IFN-γ treated HMDM analysis (positive control) 
In order to confirm the notion, that IFN-γ exerts a stimulatory effect on human 
macrophages, live cultured human macrophages were administered with IFN-γ. The direct 
effects of IFN-γ treatment were then assessed in terms of macrophage activation (pterin 







































Fig 3.2.8. HMDM vulnerability testing (positive control). 24 hours: no IFN-γ, 48 hours: 105 
units IFN-γ /ml, 72 hours: 248 units IFN-γ /ml, 96 hours: 478 units IFN-γ /ml. n= 25×106 
cells/well (12 wells). Error bars= Mean ± SEM, (p>0.05). 
 
 Analysis of lactate produced by HMDMs, over the 96 hour period, indicates that neither 
varying levels of IFN-γ nor time in incubation has decreased the survival of the HMDMs (Fig 
3.2.8).  Levels of lactate remained stable over the 96 hour period, with no significant decrease 








Fig 3.2.9. HMDMs Total neopterin and neopterin production with IFN-γ treatment. 
Neopterin produced: Black, total neopterin produced: Grey. 24 hours: no IFN-γ, 48 hours: 500 
units IFN-γ /ml added, 72 hours: 500 units IFN-γ /ml added. 2 way ANOVA: **= p<0.01, ***= 
p<0.001. Error bars= Mean ± SEM.  
 
 Levels of total neopterin increased substantially over the 96 hour time course with 
increasing doses of IFN-γ (Fig 3.2.9). Total neopterin levels significantly increased between 
the 48 hour and 72 hour period. An increase of greater significance was then observed between 
the 72 hour and 96 hour periods. 
 
Neopterin levels also increased substantially with increasing doses of IFN-γ over the 
96 hour period (Fig 3.2.9). Neopterin levels significantly increased between the 48 hour and 
72 hour periods. An increase of greater significance was then observed between the 72 hour 
and 96 hour periods. 
 
Levels of 7,8NP (the difference between neopterin and total neopterin), on the other 


















































administered. At 96 hours of incubation a significant (p<0.001) increase in 7,8 NP was 
observed from 4.12 ± 1.4 to 69.93 ± 1.4 nM. 
 
3.2.4 Dead IFN-γ treated plaque analysis (negative control) 
 To assess whether plaque culture could actively produce pterin in the absence of live 
tissue IFN-γ was administered to dead plaque tissue (frozen at -80◦C) cultured under the same 
plaque culture method as the live tissue (refer to Methods 2.4) (Refer to plaque 99 in Appendix 
Table 6.1) 
Fig 3.2.10. Dead plaques Total neopterin production with IFN-γ treatment. 2 way 
ANOVA: **= p<0.01, ***= p<0.001. Error bars= Mean ± SEM.  
 
A significant decrease in total neopterin was observed in all plaque sections, following 
the initial 24 hour period of incubation, despite the addition of IFN-γ (Fig 3.2.10).  
 
Plaque sections 1, 2, 3 and 4 experienced the most significant decrease (p<0.001) in 
total neopterin. Plaque sections 5 and 6 also experienced a significant (p<0.01) decrease in total 
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 After 72 hours plaque sections 1, 2, 3, 4, 5 and 6 had all decreased to a level below the 
LOD for the method of measurement. 
 
Levels of 7,8NP and neopterin also both decreased significantly in all plaque sections 
(p<0.001) to a level below the LOD after 72 hours of incubation.  
 
3.2.5 Live untreated plaque analysis 
Media from untreated live plaque culture was analysed to determine whether levels of 
pterin increased without IFN-γ treatment. Using this method the capability of the plaque to 
self-stimulate inflammatory cell populations, in the absence of IFN-γ, was assessed (Refer to 
plaque 95 in Appendix Table 6.1).  
Fig 3.2.11. Total neopterin production per gram of untreated live plaque. 2 way 
ANOVA: **= p<0.01, ***= p<0.001. Error bars= Mean ± SEM. 
 
Every plaque section analysed, with the exception of section 1, exhibited a significant 
decrease in total neopterin levels following the initial 24-hour incubation period (Fig 3.2.11). 
Following 48 hours of incubation no further significant decrease in total neopterin was 
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Levels of total neopterin, after the 24-hour incubation period, were significantly lower 
and significantly higher, in plaque sections 1 and 5 respectively, compared to the other plaque 
sections.  
 
After 48 hours of incubation levels of total neopterin were not significantly different 
across the plaque sections, with the exception of plaque section 5, which still had significantly 
(p<0.05) higher levels of total neopterin after both 48 and 72 hours of incubation. 
Fig 3.2.12. 7,8NP production per gram of untreated live plaque. 2 way ANOVA: 
*p=<0.05, **= p<0.01, ***= p<0.001. Error bars= Mean ± SEM. 
 
Levels of 7,8 NP decreased significantly following the initial 24 hour incubation period 
in all plaque sections, with the exception of section 1, largely mirroring the initial decrease 
observed in total neopterin levels. Following the 48 hour incubation time levels of 7,8NP were 
observed to increase slightly. However, this increase wasn’t significant (p>0.05) (Fig 3.2.12). 
 
Levels of 7,8NP measured after the initial 24 hour incubation were significantly higher, 
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however, levels of 7,8NP were not significantly different across any of the plaque sections 
(p>0.05).  
Fig 3.2.13.  Neopterin production per gram of untreated live plaque. 2 way ANOVA: *= 
p<0.05, **= p<0.01, ***= p<0.001. Error bars= Mean ± SEM. 
 
 Levels of neopterin decreased or remained stable, after the initial 24-hour incubation 
period, in all plaque sections with the exception of plaque section 1 which significantly 
increased (Fig 3.2.13). Of the 6 plaque sections analysed only sections 3 and 5 decreased 
significantly. 
  
In section 5 a significant decrease was observed following the 24 hour incubation 
period. A decrease, although less significant, was also observed between the 48 and 72 hour 
incubation periods. In plaque section 3 a significant decrease in neopterin was only observed 
between the 48 and 72 hour periods.  
 
The significant difference in neopterin levels, between plaque sections, was observed 
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significantly lower in plaque section 1 (p<0.01) and significantly higher in plaque section 5 
(p<0.01) compared to all other plaque sections. 
 
 Following the 48-hour incubation period, levels of neopterin were significantly higher 
in section 5 compared to sections 1, 2, and 4.  
 
After 72-hours of incubation plaque sections 5 and 6 still had significantly higher levels 
of neopterin in comparison to the other sections 3 and 1.  
 
3.2.6 Live IFN-γ treated plaque analysis 
IFN-γ was administered to live plaque sections to determine whether inflammatory cell 
populations, within the plaque, could be stimulated to produce pterin and therefore contribute 
to elevated levels observed in the plasma. Furthermore, the effects of IFN-γ on the health of 
live plaque cells and levels of sFlt-1 were assessed via measurement of lactate and sFlt-1 in the 
plaque culture media (Refer to plaque 97 in Appendix Table 6.1). 
 Fig 3.2.14.  Lactate produced per gram of IFN-γ treated live plaque. 48 hours: 500 units 
IFN-γ /ml, 72 hours: 500 units IFN-γ /ml.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= 
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Analysis of lactate produced by plaque sections, treated with 500 units of IFN-γ/ml, indicates 
that levels increased significantly or remained statistically stable over the course of the IFN-γ 
treatment (Fig 3.2.14). 
 
 Levels of lactate increased significantly in plaque sections 1, 2 and 3 between all 
incubation time points. Lactate levels, produced by section 4, were initially observed to 
decrease significantly between the first 24-48 hour periods of incubation, prior to IFN-γ 
administration. Levels were then observed to significantly increase across the 72 and 96 hour 
periods. No significant increase or decrease (p>0.05) in lactate was observed for sections 5 or 
6. 
 Levels measured after the first 24 hour incubation period were not significant across 
most of the plaque sections, aside from plaque sections 4 and 6 which were significantly higher 
than other sections. 
 
 Sections 1, 2 and 3 all significantly increased after the initial 24 hour incubation. 
Lactate levels in section 1, however, remained significantly higher than other sections, at all 
time points, aside from section 6. Lactate levels, between the 24 and 48 hour incubation 
periods, decreased in section 4. However, at the 72 and 96 hour incubation periods, no 
significant difference was observed between lactate levels in section 4 and those observed in 
sections 2 or 3.  
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Fig 3.2.15.  Total neopterin produced per gram of IFN-γ treated live plaque. 48 hours: 500 
units IFN-γ /ml, 72 hours: 500 units IFN-γ /ml.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= 
p<0.001. Error bars= Mean ± SEM. 
 
A significant increase in total neopterin was observed for all plaque sections over the 
total 96 hour incubation period with the addition of IFN-γ (Fig 3.2.15.). 
 
 Total neopterin levels increased, only in sections 2 and 3, in the absence of IFN-γ over 
the first 48 hours of incubation. Upon addition of IFN-γ to the plaque culture media, after 48 
hours of incubation, total neopterin levels were observed to significantly increase for plaque 
sections 2, 4, 5 and 6. 
 
 After the second IFN-γ dose was added, levels of total neopterin significantly increased 
for all plaque sections. 
 
Total neopterin produced by the plaque sections varied. However, a similar trend in 
total neopterin up-regulation was observed, after IFN-γ treatment, with the exception of 
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 After addition of the first IFN-γ dose neopterin levels produced were significantly 
higher in plaque sections 2, 3, and 6 compared to the other sections. At 96 hours levels of total 
neopterin produced by sections 3 and 6 were significantly higher than all other sections. 
Fig 3.2.16.  7,8NP produced per gram of IFN-γ treated live plaque. 48 hours: 500 units 
IFN-γ /ml, 72 hours: 500 units IFN-γ /ml.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= 
p<0.001. Error bars= Mean ± SEM. 
 
A general increase in 7,8 NP was observed with the addition of IFN-γ to plaque sections 
(Fig 3.2.16.). Levels of 7,8 NP increased or remained stable after the first IFN-γ dose with the 
exception of sections 1 and 3 which significantly decreased.  
 
After the second dose of IFN-γ 7,8NP was significantly upregulated in all plaque 
sections. These levels were significantly higher, after the first and second dose of IFN-γ, in 
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No significant difference, in 7,8 NP levels, were observed between any of the other 
plaque sections besides sections 1 and 4, which produced significantly lower levels, after 72 
hours of incubation. 
Fig 3.2.17.  Neopterin produced per gram of IFN-γ treated live plaque. 48 hours: 500 units 
IFN-γ /ml, 72 hours: 500 units IFN-γ /ml.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= 
p<0.001. Error bars= Mean ± SEM. 
 
A significant increase in neopterin production was observed for all plaque sections after 
the first IFN-γ dose at 48 hours. On average a 4 fold increase in neopterin was observed after 
the first dose of IFN-γ. A significant increase in neopterin was then observed again for all 
plaque sections after the second dose of IFN-γ (Fig 3.2.17.). 
 
No significant difference was observed, between levels of neopterin produced in the 
initial 24 and 48 hour incubation periods, before the administration of IFN-γ. 24 hours after the 
initial IFN-γ dose was administered levels of neopterin had increased significantly for all 
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 After the second dose of IFN-γ, levels of neopterin produced were still significantly 
higher in section 6 compared to other plaque sections. Levels of neopterin were also 
significantly higher in sections 2 and 4 compared to sections 1, 3 and 4. 
Fig 3.2.18.  sFlt-1 produced per gram of IFN-γ treated live plaque. 48 hours: 500 units IFN-
γ /ml, 72 hours: 500 units IFN-γ /ml.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= p<0.001. 
Error bars= Mean ± SEM. 
 
IFN-γ, generally, did not increase the level of sFlt-1 produced by the atherosclerotic 
plaque (Fig 3.2.18.). A decrease or insignificant change in sFlt-1 was observed for all plaque 
sections, with the exception of plaque section 4 which exhibited an increase in sFlt-1 after the 
first dose of IFN-γ. However, sFlt-1 levels in section 4 did not significantly change overall 
between the initial and final incubation periods. 
 
Levels of sFlt-1 remained significantly higher in sections 3 and 4 compared to other 
sections after the addition of IFN-γ. sFlt-1 remained significantly lower in plaque section 5 
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3.2.7 Live PMA treated plaque analysis 
In order to determine the capability of T-cell populations to stimulate inflammatory 
cells within the plaque, the sections were treated with PMA. The media was then analysed for 
pterin content to assess the extent of macrophage activation occurring as a result of T-cell 
stimulation. The levels produced indicate the potential of the plaque to contribute to arterial 
pterin levels as a result of inflammatory T-cell stimulation (Refer to plaque 103 in Appendix 
Table 6.1).  
Fig 3.2.19.  Total neopterin produced per gram of PMA treated live plaque. 200nM PMA 
media was added at 24, 48 and 72 hour incubation periods.  2 way ANOVA: *= p<0.05, **= 
p<0.01, ***= p<0.001. Error bars= Mean ± SEM. 
 
 No significant change in total neopterin was observed, after the first dose of PMA, in 
any of the plaque sections. Total neopterin production increased significantly in all plaque 
sections after the second dose of PMA, indicating a 24 hour lag period in total neopterin up-
regulation after the initial PMA dose (Fig 3.2.19.). 
 
After the third dose of PMA levels of total neopterin increased significantly in sections 
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No significant difference in total neopterin levels, measured at the 24 and 48 hour 
incubation periods, were observed between the plaque sections with the exception of section 3 
which produced significantly higher levels of total neopterin, at all incubation time points.  
 
Measurements at 72 and 96 hours of incubation were significantly lower in sections 4 
and 6 and significantly higher in sections 1 and 3 compared to other sections.  
Fig 3.2.20.  7,8NP produced per gram of PMA treated live plaque. 200nM PMA media was 
added at 24, 48 and 72 hour incubation periods.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= 
p<0.001. Error bars= Mean ± SEM. 
 
The same 24 hour delay, observed in total neopterin up-regulation, was observed for 
7,8 NP after the first dose of PMA. 24 hours after the second dose of PMA a significant increase 
in 7,8NP was observed for all plaque sections (Fig 3.2.20.). 
  
Plaque sections 1, 2 and 3, which were observed to increase significantly in total 
neopterin levels after the 3rd dose of PMA, exhibited a significant decrease in the level of 7,8 
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after the 3rd dose of PMA. Section 6 was the only section which produced a higher level of 7,8 
NP, following the 3rd dose of PMA, although this increase was insignificant.  
 
 No significant difference was observed between any of the plaque sections over the first 
48 hours of incubation. However, section 3 produced significantly higher levels of 7,8 NP, in 
comparison to all other plaque sections, after the second dose of PMA. 
 
 After the 3rd dose of PMA levels produced by section 3 had significantly decreased to 
a level not significantly different from that of sections 1 or 5.  
 
Levels of 7,8 NP produced, after the 2nd and 3rd doses of PMA, by sections 4 and 6 
were significantly lower than all other sections. 
Fig 3.2.21.  Neopterin produced per gram of PMA treated live plaque. 200nM PMA media 
was added at 24, 48 and 72 hour incubation periods.  2 way ANOVA: *= p<0.05, **= p<0.01, 
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A general increase in neopterin was observed in all plaque sections following repeated 
doses of PMA. 24 hours after the 2nd dose of PMA neopterin levels significantly increased in 
all plaque sections (Fig 3.2.21).  
 
After the 3rd PMA dose a further significant increase in neopterin production was 
observed with the exception of section 6, which didn’t significantly change, between the 72 
and 96-hour incubation periods.   
 
 Levels of neopterin produced by the plaque sections, as observed in the 7,8 NP and total 
neopterin analysis, did not significantly change, between the 24 and 48 hour incubation periods, 
in any of the plaque sections. 
  
Section 3 had produced significantly higher levels of neopterin, 24 hours after the 
second dose of PMA, compared to the other plaque sections. Section 4, on the other hand, 
produced significantly lower levels of neopterin, 24 hours after the second dose, compared to 
all other plaque sections.  
 
Levels of neopterin remained significantly higher in section 3, 24 hours after the 3rd, 
dose of PMA and were significantly lower in sections 4 and 6 compared to the other plaque 














3.2.8 Live IFN-γ and PMA treated plaque analysis 
 Plaque sections were treated, initially with PMA followed by IFN-γ, to assess whether 
IFN-γ could further promote the effects of macrophage activation occurring as a result of T-
cell stimulation by PMA (Refer to plaque 106 in Appendix Table 6.1). 
Fig 3.2.22.  Total neopterin produced per gram of PMA and IFN-γ treated live plaque. 
200nM PMA media was added at 24 and 48 hour incubation periods. IFN- γ was added at the 
72 hour incubation period.  Two-way ANOVA: *= p<0.05, **= p<0.01, ***= p<0.001. Error 
bars= Mean ± SEM. 
 
 PMA generally caused a delayed up-regulation of total neopterin whereas the effects of 
IFN-γ were more immediate.  Levels of total neopterin significantly decreased between the 24 
and 48-hour incubation periods, following administration of PMA, with the exception of plaque 
section 2 (Fig 3.2.22.). 
  
After the second dose of PMA levels of total neopterin increased to a level not 
significantly different from the initial 24 hour reading before PMA was added. This increase 
occurred in all plaque sections aside from section 4, which produced significantly higher levels, 
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After IFN-γ treatment, over the final 24 hour period, the level of total neopterin 
produced by all plaque sections increased significantly 
 
Aside from the 48-hour incubation period levels of total neopterin, produced by section 
2, were significantly lower than in any other section. After the second dose of PMA section 
four produced significantly higher levels of total neopterin compared to the other plaque 
sections.  
 
There was no significant difference, in total neopterin production observed between the 
plaque sections 24 hours following treatment with IFN-γ, aside from section 2 which was 
significantly lower and section 4 which was lower but tended towards insignificance (p<0.05).  
Fig 3.2.23.  7,8 NP produced per gram of PMA and IFN-γ treated live plaque. 200nM 
PMA media was added at 24 and 48 hour incubation periods. IFN- γ was added at the 72 hour 
incubation period.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= p<0.001. Error bars= Mean 
± SEM. 
 
A general decrease in 7,8NP was observed, over the initial 72 hours of incubation, 
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3 and 6 following the initial dose of PMA. In sections 5 and 4 levels of 7,8 NP were observed 
to decrease but this decrease was insignificant.  An increase in 7,8 NP was observed in section 
2 after the initial PMA treatment, but the increase also tended toward insignificance (p<0.05).  
 
Following the second incubation with PMA, between 48 and 72 hours, levels of 7,8 NP 
significantly decreased in sections 1, 2 and 3, insignificantly decreased in section 5 and 
increased significantly in sections 4 and 6. 
  
Incubation with IFN- γ, in the final 24 hours, resulted in a significant decrease in 7,8 
NP found in sections 4, 5 and 6. 7,8 NP in sections 1 and 3 increased insignificantly after 
incubation with IFN- γ. Section 2 was the only section which produced significantly increased 
levels of 7,8 NP following IFN-γ treatment. 
Fig 3.2.24.  Neoterin produced per gram of PMA and IFN-γ treated live plaque. 200nM 
PMA media was added at 24 and 48 hour incubation periods. IFN- γ was added at the 72 hour 
incubation period.  2 way ANOVA: *= p<0.05, **= p<0.01, ***= p<0.001. Error bars= Mean 
± SEM. 
 Levels of neopterin, as was observed in the analysis of total neopterin, generally 
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which levels decreased after the first PMA dose. This lag period, after the initial dose of PMA, 
was observed in all plaque sections (Fig 3.2.24.). 
 
 IFN-γ treatment, in the last 24 hours of incubation, resulted in a significant increase in 
neopterin for all plaque sections. 
 
 Levels of neopterin did not vary greatly across the different plaque sections with the 
exception of section 2 and 5. After treatment with IFN-γ levels of neopterin found in section 2 
were significantly lower than all other plaque sections. Section 5, on the other hand, had 























4.1 Direct associations in the CDCS plasma between alcohol consumption 
and BNP versus the measured biomarkers neopterin, 7,8NP and sFlt-1 
 
The VEGF system, generally comprising the major angiogenic molecules responsible 
for controlling vascular growth and function, is predominantly thought to have a protective role 
against atherosclerotic progression. However, contrary to this notion, studies have also shown 
that overexpression or chronic VEGF expression can contribute to pro-atherosclerotic 
processes (Couffinhal et al., 1997; Inoue et al., 1998). As sFlt-1 is known to sequester VEGFA 
molecules, preventing the downstream angiogenic response, it may exert differing effects on 
atherosclerotic progression. Using multiple regression analyses, attempts were made to assess 
whether a relationship existed between sFlt-1 and CVD events in acute coronary syndrome 
patients. In order to determine which known CVD risk factors may be used to account for 
variance, when assessing a potential association between sFlt-1 and CVD, a general linear 
model was used. Acute coronary syndrome patient plasma was analysed for sFlt-1 in 
association with other known associates of CVD including BNP, alcohol consumption per 
week, diastolic BP, heart rate, BMI and gender (Fig 3.1.2).  
 
Markers of systemic immune system activation, neopterin and 7,8 NP,  have also been 
associated with vascular inflammation and stenosis, which often leads to the development of 
severe cardiovascular events (Zouridakis et al., 2004). For this reason these markers were also 
compared to the same CVD risk factors in order to determine whether the same associations 
arose between neopterin (Fig 3.1.4), total neopterin (Fig 3.1.3) and 7,8NP (Fig 3.1.5) that 
occurred in sFlt-1. 
 
Aside from gender and BMI which were insignificant and heart rate which tended 
toward insignificance (p=0.035), all other covariates were found to be highly associated in the 
general linear model of sFlt-1 associations. However, the same could not be said for the 
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neopterin data. The only covariate significantly associated with both, neopterin and sFlt-1, was 
BNP, which exhibited a marginally significant association (p=0.024) with neopterin and a 
highly significant association (p=0.007) with sFlt-1 (Table 3.1.2 and Table 3.1.4 in Results). 
In support of these findings recent results, from a study assessing the utility of multiple markers 
in determining the risk of chronic heart failure, also found a significant, but moderate (R=0.54), 
association between sFlt-1 and BNP (Ky et al., 2012). Similarly, a significant correlation was 
observed, between neopterin and BNP, in patients undergoing left ventricular remodelling after 
experiencing a MI (Dominguez-Rodriguez, Abreu-Gonzalez, Avanzas, Laynez-Cerdeña, & 
Kaski, 2010). Furthermore, when added to a multivariable Cox model of acute coronary 
syndrome event risk, containing C-reactive protein and BNP, the further addition of neopterin 
significantly improved the HF-risk prediction model (P = 0.005) (Nazer et al., 2011a). The 
results, therefore, suggest that the levels of sFlt-1 and neopterin, like BNP, may be associated 
with ventricular wall stress potentially occurring as a result of an acute coronary event.   
Interestingly BMI was significantly associated with neopterin, but not sFlt-1 (Table 3.1.2 and 
Table 3.1.4 in Results). Suggesting that oxidative stress (causing the increased oxidation of 
7,8NP to neopterin) may be associated with an individual’s BMI.  
 
No covariates shared significance with both neopterin and 7,8NP. Likely due the 
production of neopterin being a direct result of 7,8NP oxidation. However, levels of 7,8 NP 
and total neopterin, like sFlt-1, were significantly associated with an individual’s alcohol 
consumption. Typically alcohol is found to have a U-shaped association with inflammation, 
with non-drinkers and heavy drinkers having higher levels of inflammation (Kloner & 
Rezkalla, 2007). Past studies have shown that non-drinkers and heavy drinkers had higher C-
reactive protein (CRP) concentrations and a higher risk of CVD than moderate drinkers (Imhof 
et al., 2001). The results derived from this dataset suggest that like CRP, produced in response 
to IL4 released from macrophages (Du Clos, 2000), 7,8 NP levels rise with higher levels of 
alcohol consumption. Suggesting that increased inflammation, with higher levels of alcohol 
consumption, may be in part be associated with increased macrophage activation.  
 
The results of a recent study, also concerning the U-shaped association between alcohol 
and inflammation, indicate that ethanol stimulates endothelial angiogenic activity through 
cross talk between the notch and kinase insert domain (KDR) signalling pathways and also 
upregulates KDR (Morrow, Hatch, Hamm, Cahill, & Redmond, 2014). Excess alcohol 
consumption may therefore increase the risk of CVD, as a result of overactive 
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angiogenesis/vascular remodelling, causing chronic inflammation, mediated by the KDR 
receptor pathway.  In agreement with these findings, a strong direct correlation (p=0.001) was 
observed between levels of sFlt-1 in the patient cohort and alcohol consumption per week. 
Since levels of sFlt-1 were lower at lower levels of alcohol consumption the ability of sFlt-1 to 
negate VEGF stimulated angiogenesis is less effective. For this reason the consumption of low 
levels of alcohol may contribute to VEGF stimulated angiogenesis, which is hindered to a lesser 
extent by sFlt-1, by upregulating KDR and further stimulating it. The data produced also 
potentially explains the protective effects of moderate alcohol consumption. Since sFlt-1 
hinders the normal angiogenic effect, of VEGF binding to KDR, alcohol may provide an 
alternative route of angiogenic up-regulation resulting in a healthy level of vascular 
remodelling and repair. 
 
Direct correlations also identified a significant association between levels of 7,8 NP, 
total neopterin and alcohol consumption, supporting the already identified relationship between 
alcohol and inflammation. Aside from alcohol consumption the only other direct correlations 
observed between measured variables were between sFlt-1 and BNP (p=0.027) (Fig 3.1.6). 
This may also be explained by the notion that sFlt-1 is upregulated in hypoxic conditions, 
which classically arise in ischaemia, a condition which can present significant stress on the 
ventricular walls such as in the case of MI (Goetze et al., 2003).  
 
4.2 Predictive capacity of sFlt-1, neopterin, 7,8NP and total neopterin in 
determining ACD, TCVE and CVD death  
 
 Univariate analyses of all cause death (ACD) revealed that higher levels of total 
neopterin, 7,8 NP and sFlt-1 were all significantly associated with ACD, whereas, higher levels 
of neopterin were generally not. Total neopterin, 7,8 NP and sFlt-1 are therefore all independent 
markers of ACD post-acute coronary event. 
 
sFlt-1 levels measured in a similar study, of patients with stable acute coronary disease, 
were not found to be a significant independent predictor (p=0.125) of any adverse outcomes 
(hazard ratio = 0.57) (Matsumoto et al., 2012). Contrary to this, plasma levels of sFlt-1 
measured in the current study indicate that sFlt-1 is a highly significant independent predictor 
of ACD (p<0.001) (Fig 3.1.11, Table 3.1.25) and CVD death (p=0.001) (Fig 3.1.13, Table 
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3.1.29) over a 10-year period. Furthermore, a higher than median sFlt-1 level, when analysed 
in a Cox proportional analysis alongside higher than median BNP, alcohol consumption and 
age, corresponds to a 2-fold higher rate of mortality (Hazard ratio=1.990, p=0.003) (Table 
3.1.26).  Some of the relationship observed between ACD and sFlt-1 can be explained by the 
significant relationship between CVD death and sFlt-1 (p=0.001). The data suggests that sFlt-
1 not only exhibits prognostic utility in determining the risk of ACD, but also exhibits 
predictive capabilities in determining the risk of CVD death. A notion which is further 
supported by its significant predictive capacity in association with the covariates BNP and age 
at baseline (Table 3.1.30). Since the risk of adverse events is 2 times higher in patients with 
elevated sFlt-1 (above 117.3 pg/ml), this level may be used clinically as a comparative standard 
in assessing the level of risk management required. Providing intensive management of 
coronary risk factors is essential for preventing secondary events. However, because the 
progression of atherosclerosis is slow, it is likely that continuous activation of intramural 
inflammation plays a role in the occurrence of cardiovascular events. This may not be 
accounted for by levels of sFlt-1 until a sufficient level of ischaemia occurs, to present a 
hypoxic condition, resulting in its up-regulation.         
 
 Levels of total neopterin and 7,8 NP, were found in this study, to be significantly 
associated with ACD (Fig 3.1.2, Fig 3.1.8), which is in agreement with past research relating 
inflammation to risk of death post CVD event (Andersson, Libby, & Hansson, 2010). Previous 
to this study neopterin has been presented as an independent marker of ACD and acute coronary 
events after an initial acute coronary event (Ray et al., 2007). However, it is unclear whether 
the study differentiates between 7,8NP and neopterin, suggesting that the two have been 
measured together as total neopterin. This being said enhanced T-cell activity, that results in 
increased production of interferon-γ, is implicated in the pathogenesis of CVD (Garcia-Moll, 
D. Cole, et al., 2000; Liuzzo et al., 2000). Total neopterin production, by monocytes and 
macrophages, is primarily in response to stimulation by interferon-γ released by activated T-
lymphocytes (Berdowska & Zwirska‐Korczala, 2001). Therefore, the levels of Total neopterin 
observed may reflect the level of cell-mediated immunity within individuals which could 
contribute to mortality post CVD event.  
 
Both 7,8NP and total neopterin were not found to exhibit a significant individual 
capacity in predicting CVD death (Fig 3.1.4, Fig 3.1.10). However, in combination with 
alcohol consumption, age at baseline and BNP, higher levels of both 7,8NP and Total neopterin 
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did significantly (p=0.046 and p=.032 respectively) predict CVD death (Table 3.1.12, Table 
3.1.24). Therefore, in combination with these factors, 7,8NP and Total neopterin show promise 
in their capacity for predicting the risk of CVD death, having the potential to aid in determining 
the need for management of coronary risk factors. 
 
Although higher 7,8 NP was independently associated with ACD the case was not the 
same for neopterin. The risk of ACD is therefore suggested to have a lesser relationship to 
baseline oxidative stress. However, when combined in a Cox proportional hazard model, (Table 
3.1.14) neopterin was indicated as a significant predictor (p=0.013) of ACD, alongside alcohol 
consumption, age at baseline and BNP, with a hazard ratio of 5.614. Neopterin may therefore 
be of more substantial prognostic use in combination with these other indicators compared to 
alone. Similarly Nazer et al., 2011 found that neopterin significantly improved the Cox 
proportional HF-risk prediction model (p = 0.005) already encompassing C-reactive protein 
and BNP. No relationship was observed between neopterin and CVD death, alone (Fig 3.1.7, 
Table 3.1.17) or in a Cox proportional regression model (Table 3.1.18), suggesting that the 
relationship between neopterin and ACD is not significantly contributed to by CVD death. 
Instead patients dying, in association with high levels of the neopterin, may be a result of 
alternative illness also associated with high levels of oxidative stress. 
  
Despite the prognostic utility, exhibited by sFlt-1, 7,8 NP, neopterin and total neopterin, 
no significant association was found, alone or in combination with other CVD factors, between 
these markers and total cardiovascular events (TCVE). CVD is a dynamic process involving 
many factors, which may contribute to its progression and severity. In the case of an acute 
event certain markers may be elevated transiently, which has been shown in the case of sFlt-1 
and total neopterin (Kaski et al., 2008; Onoue et al., 2009). A more accurate way, of 
determining an association with TCVE, would therefore be to serially evaluate levels in 
patients at risk indicating whether spikes in these markers correspond to an event. Likewise, 







4.3 Plasma levels of sFlt-1, 7,8 NP, total neopterin and neopterin in patients 
with late stage atherosclerosis in the carotid artery 
 
In comparison to age and gender matched healthy controls, levels of sFlt-1 were 38 
times higher in males and 24 times higher in females (Fig 3.2.1), suggesting that sFlt-1 levels 
are significantly elevated in patients with a developed atherosclerotic occlusion. These elevated 
levels are likely due to the significant ischaemic condition downstream of the occlusion, which 
results in hypoxic up-regulation by HIF-1 (Sandner et al., 1997), supporting previous evidence 
of higher sFlt-1 levels in acute stages of CVD (Kapur et al., 2011). Levels of sFlt-1 were not 
significantly different between males and females or at different ages indicating that this up-
regulation occurs regardless of age or gender. Levels of sFlt-1 were also significantly higher 
compared to levels found in the CDCS cohort, further indicating that a transient up-regulation 
of sFlt-1 is likely and that post recovery these levels decline. Although the two cohorts are from 
differing facets of CVD, similar results have been found upon comparing sFlt-1 in patients with 
acute ischaemia to sFlt-1 in the same patients after recovery (Chung, Lydakis, Belgore, Blann, 
& Lip, 2002). 
 
Levels of total neopterin were also significantly elevated for both males and females in 
comparison to the healthy age and gender matched controls. Also no significant difference was 
observed between age groups and gender (Fig 3.2.4). Higher levels of total neopterin have been 
observed in patients with carotid atherosclerosis in a previous study (Weiss et al., 1994), 
indicating that the level of cell-mediated immunity within individuals which could be 
attributable to presence of atherosclerosis. 
 
 In comparison to levels observed in the CDCS cohort (median: 94.5 nM), levels found 
in the plasma of the carotid endarterectomy patients (median: 50.3 nM) were significantly 
lower. Therefore, macrophage activation may be a chronic response which occurs throughout 
atherosclerotic development and remains elevated long after a CVD event has occurred. 
However, due to differences in the two cohorts these levels are not directly relatable. In order 
for direct comparisons to be made, serially evaluated levels in advanced atherosclerosis 




Levels of neopterin largely followed the same trend as total neopterin, suggesting that 
elevated oxidative stress occurs in CVD patients regardless of age or gender (Fig 3.2.2). 
However, levels of 7,8NP were significantly lower in the female control group than the female 
and male endarterectomy groups and the male control group. Males therefore appear to have 
higher healthy levels of macrophage activation, which do not significantly differ in 
atherosclerosis, as opposed to females whose levels appear to increase depending on 
atherosclerosis. This may partially, among other factors, account for the higher levels of CVD 
observed in males compared to females (Go et al., 2014) as inflammation has been closely 
related to the severity of CVD.   
 
In patients prior to undergoing the endarterectomy procedure, a significant correlation 
was observed between plasma sFlt-1 and both total neopterin (Fig 3.2.7) and 7,8 NP (Fig 3.2.6). 
This relationship was not observed in patients post recovery from MI or unstable angina. Based 
on this finding, it would appear that levels of sFlt-1 increase somewhat proportionally to the 
amount of cell mediated inflammation in atherosclerosis and that these levels are reduced post 
recovery after the plaque has become unstable or an MI has occurred. Immune cell mediated 
inflammatory processes may therefore play a role in the hypoxia driven up-regulation of sFlt-
1 by HIF-1. Also after recovery from an event oxygen reperfusion to the once ischaemic area, 
distal to the atherosclerotic plaque, may cause a down-regulation in sFlt-1. In support of this 
previous studies have identified a significant association between levels of the inflammation 
and sFlt-1 in, the systemic inflammatory disorder, pre-eclampsia, associated with placental 
hypoxia (McKeeman, Ardill, Caldwell, Hunter, & McClure, 2004; Nevo et al., 2006).  
 
Plasma neopterin did not show the same relationship with sFlt-1 that 7,8NP did. 
Indicating that, although levels of oxidative stress may be elevated in these patients, little or no 
relationship exists between it and the hypoxic up-regulation of sFlt-1. 
 
4.4 The presence of live inflammatory cell populations within 
atherosclerotic plaques 
 
HMDM cells produce basal levels of both 7,8-NP and neopterin, which significantly 
increase with treatment of IFN-γ (Fig 3.2.9). Furthermore, the health of these cells was not 
significantly affected by the 96 hour incubation in RPMI or treatment with IFN-γ as a steady 
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state of lactate production was observed across the 24 hour incubation increments (Fig 3.2.8). 
Upon initial stimulation with IFN-γ a 2.4 fold increase in total neopterin concentration, 
produced by the HMDM cells, (From 40±3.54 nM to 94.4±9.516 nM) was observed, 
confirming previous results for the effectiveness of IFN-γ in stimulating total neopterin 
production (Werner et al., 1990; Wirleitner et al., 2002). The ratio of 7,8 NP to neopterin 
produced fell significantly in favour of neopterin, suggesting that much of the 7,8NP produced 
had been oxidized. Although a classical ratio of 2:1 for 7,8 NP to neopterin has been observed 
for arterial blood (Weiss et al., 1992), and the ratio observed in arterial blood here was more 
like 1:1, the levels observed here serve more to represent the potential for activation by IFN-γ 
as 7,8 NP produced may easily be effected by the surrounding testing conditions.    
 
Compared to levels of total neopterin produced by HMDMs in a study by Wirleitner et 
al., macrophages in this experiment produced significantly higher levels after treatment with 
half the dose of IFN-γ (1000 U/ml compared to 500 U/ml) (Wirleitner et al., 2002). However, 
basal levels of total neopterin were much higher in this study, which may explain, in part the 
higher levels observed after treatment.  
 
Unsurprisingly, levels of total neopterin produced by a plaque section which had been 
freeze-thawed were negligible (Fig 3.2.10). Although significant amounts of 7,8NP were 
observed in the plaque culture media after 48 hours, these levels dropped below the limit of 
detection rapidly, suggesting that what was observed had been washed off the plaque rather 
than produced by its cellular constituents.  
 
Without stimulation with IFN-γ or PMA levels of both 7,8 NP and neopterin, produced 
per gram of atherosclerotic plaque, significantly decreased within 24 hours of incubation (Fig 
3.2.11). 7,8 NP levels, which significantly decreased after the first 48 hours of incubation, 
remained stable throughout the next 24 hours (Fig 3.2.12), whereas the decrease in neopterin 
consistently occurred over the three 24 hour incubation periods (Fig 3.2.13). Therefore, it 
would appear that the amount of macrophage activation taking place consistently decreases 
during the incubation procedure. Furthermore, a high proportion of the 7,8 NP produced 
oxidises to neopterin. Levels of both 7,8 NP and neopterin largely varied across the plaque 
sections, indicating that the proportion of inflammatory cell populations may have also varied 
between plaque sections, which was to be expected as atherosclerotic plaques do not usually 




Lactate production, although unchanged over 96 hours in the HMDM culture, generally 
increased in the plaque cell culture (Fig 3.2.14). This lactate increase is more likely due to 
gradual infiltration of the RPMI 1640 media into the plaque intima, than due to addition of 
IFN-γ, as the initial increase occurs prior to IFN-γ dosing. 
 
After the initial dose of IFN-γ a general increase in total neopterin was observed in the 
live plaque sections (Fig 3.2.4). Like the HMDM cell culture a much more significant increase 
in both 7,8 NP (Fig 3.2.15) and neopterin (Fig 3.2.16) was observed after the final 500 U/ml 
dose of IFN-γ was administered. The macrophages may therefore either become primed by the 
first dose of INF-γ or experience some delay in production requiring longer than 24 hours 
before the full effect is observed. Much lower levels of both neopterin and 7,8 NP were 
produced, even after the final dose of IFN-γ , than those measured in the HMDM cell culture. 
Similarly, in past cell culture analysis, levels produced by HMDM cells were higher, even at 
lower (100 U/ml) doses of IFN-γ (Wirleitner et al., 2002). Suggesting that the immune cell 
populations within the plaque were either less sensitive to IFN-γ or that there were less of them. 
This being said levels of total neopterin measured 24 hours after the second dose of IFN-γ were 
in the nM concentration levels (ranging from 4.1±0.2 nM/g to 9.6±0.01 nM/g). These plaques 
are therefore capable of significant macrophage activation in the presence of IFN-γ, which may 
contribute to levels in the plasma higher than that identified in the blood of a healthy individual 
(6.7 ± 1.5 nM) (Murr. et al., 2005). Furthrmore, levels of 7,8 NP alone, produced by the plaque 
section, also ranged into the nM concentrations (from 1.7±0.06 nM/g to 6.8±0.0 nM/g) which 
could contribute to higher blood levels than healthy individuals (approximately 5.8 nM/L) 
(Flavall et al., 2008). This may indicate why much higher levels of 7,8 NP and neopterin were 
observed in the plasma of these endarterectomy patients. 
 
Over the 96-hour incubation period levels of sFlt-1 either decreased gradually or did 
not change (Fig 3.2.17). Indicating that, although the cells were producing sFlt-1, IFN-γ had 
no significant effect on these levels. Taking into account the mechanism of sFlt-1 upregulation, 
the reason behind the gradual down-regulation may lie in the HIF-1 transcription factor. HIF-
1 is a heterodimeric transcription factor consisting of subunit α, which is oxygen-sensitive and 
rapidly degraded/inactivated during normoxia, and subunit β, which is constitutively active 
(Semenza, 2000). Since the conditions of the plaque culture were atmospheric, the plaque 
experienced relative hyperoxia limiting HIF-1’s ability for transcription of sFlt-1. In order to 
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determine whether levels of sFlt-1 could be upregulated within the plaque, incubation in 
hypoxia is required which could not be covered under the scope of this project. However, if 
sFlt-1 can be upregulated within the plaque, the upregulated levels may contribute to those 
observed in the plasma making it a valuable aspect of future research on the subject.  
 
A 48-hour delay period was observed in total neopterin upregulation following initial 
dosing with 200nM PMA (Fig 3.2.18). However, following the second dose of PMA, a 
significant 6-fold increase was observed on average across the plaque sections. This delay 
period suggests that either the process of IFN-γ production by Th1 cells in the atheroma is not 
a rapid process or that the process of total neopterin production by macrophages in response to 
IFN-γ causes delay. Since we have shown previously, in the IFN-γ treated plaque, that the latter 
is not the case, it is likely that the PMA interaction with Th1 cells is responsible. However, the 
ultimate up-regulation of total neopterin to nM levels with the addition of PMA, shows that T-
cell stimulation, by native molecules such as IL-12 or 18, may be another step in production of 
total neopterin levels observed in acute CVD patients. Supporting this statement, findings from 
a past study of monoclonal T-cell proliferation in atherosclerotic plaques, indicates that 
unstable angina is associated with the expansion of interferon-γ–producing T lymphocytes 
within the plaque (Liuzzo et al., 2000). Indicating that total neopterin, being upregulated by 
this IFN-γ, may be a valuable marker of these events.  
 
 Likewise, after a 48-hour delay, significant increases in both neopterin (Fig 3.2.20) 
and 7,8NP (Fig 3.2.19) were observed across all plaque sections. A decrease in 7,8 NP was 
observed in the majority of the plaque sections 24 hours after the 3rd dose of neopterin (at 96 
hours), whilst an increase in neopterin was observed. Therefore, between 72 and 96 hours of 
incubation, there was a significant oxidative event suggesting the presence of radical species 
in the plaque sections. This is likely, as recent evidence shows advanced human atheroma 
contain high levels of myeloperoxidase containing macrophages capable of producing the 
pro-oxidant species, HOCl (Sugiyama et al., 2001). 
 
 The delay in total neopterin production was much more evident in the plaque culture 
analysis of PMA and IFN-γ together (Fig 3.2.21). Levels of total neopterin were observed to 
decrease 24 hours after the first dose of PMA whereas at 72 hours incubation (24 hours after 
the second dose) levels significantly increased. Providing more evidence for PMAs delayed 
upregulation of IFN-γ. Levels of both 7,8 NP and neopterin however were much lower in all 
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the plaque sections compared to other plaques. This is likely because cellular constituents 
vary between plaques. Making classification of an average plaques makeup difficult, if not 
impossible to derive. Similarly the cellular makeup between sections in a plaque are highly 
varied. This is supported by different levels of response to PMA in the plaque sections, with 
some sections producing significantly more 7,8 NP (Fig 3.2.22) than others. Although levels 
varied between sections a similar increase in oxidation of 7,8NP was observed over the 
plaque sections supporting that pro oxidants were being generated (Fig 3.2.23), 
 
4.5 Summary  
 
The results of this study have provided supportive evidence for the potential prognostic 
use of sFlt-1, total neopterin, and 7,8 NP via significant associations between these factors and 
ACD post-acute angina or MI. Furthermore sFlt-1 levels above 117 pg/ml were significantly 
associated with CVD death, supporting its predictive capacity in determining CVD risk using 
methods described in this research. The use of this marker alone or in combination with the 
covariates BNP, drinks per week and age at baseline may therefore, with further evidence, 
prove to be a valuable biomarker of CVD events. Alcohol consumption previously, shown to 
have a U shaped association with CVD, may in part be explained by its association with sFlt-
1 levels in the plasma of acute coronary syndrome patients. Potentially linking the consumption 
of alcohol with angiogenesis via alternative activation of the VEGFR KDR. Significant 
associations observed between levels of sFlt-1 and total neopterin provides new evidence of a 
relationship between inflammatory cell activation and the hypoxic upregulation of sFlt-1. A 
process, which in future may support evidence for the association between sFlt-1 and CVD. 
Lastly the research indicating varied levels of live macrophage and T-cell populations within 
atherosclerotic plaques opens new avenues for research into the production of inflammatory 
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Age Gender Plaque 
location 
Symptoms Stenosis 
42 64 M Left ICA TIA 75% 
44 63 F Left ICA TIA 80-95% 
50 88 M Left ICA Stroke, TIA 70-80% 
51 78 M Right ICA TIA 79% 
53 64 M Left ICA Critical limb ischaemia 70-79% 
55 76 M Right ICA Stroke 70% 
58 70 M Left ICA TIA 70-79% 
60 81 M Right ICA Stroke 70-79% 
63 63 F Left ICA Stroke 80-95% 
66 81 M Right ICA TIA 90% 
67 55 F Left ICA TIA 60-69% 
68 81 F Left ICA TIA 80-95% 
69 83 M Left ICA TIA 60-69% 
70 72 F Left ICA Dysphasia, Slurred speech 60-69% 
74 67 M Right ICA Stroke, left side weakness, TIA 80-95% 
76 68 M Left ICA Stroke 85-90% 
77 71 M Right ICA Stroke 80-95% 
79 75 M Left ICA Stroke 80-95% 
83 54 F Right ICA TIA/left arm weakness 79% 
86 81 M Left ICA Stroke 70% 
87 67 M Right ICA Stroke 70-79% 
89 72 M Right ICA TIA 90% 
*95 
49 M Left ICA 
Stroke, Retinal Ischemia, 
Familial Hypercholesterolemia 60-69% 
*97 84 M Left ICA TIA 70% 
98 69 M Right ICA TIA, Left sided weakness 50-69% 
*99 76 M Right ICA Stroke 70% 
100 67 F Right ICA TIA 70-79% 
101 87 F Left ICA Stroke 80% 
102 81 M Left ICA TIA 70% 
*103 71 F Right ICA TIA 70-79 
*106 79 F Right ICA TIA, Stroke 80% 
Table 6.1. General summary of endarterectomy patients. General medical information 
regarding the endarterectomy patients. TIA (Transient ischaemic attacks), ICA (Internal carotid 





Patient number sFlt-1 (pg/ml) Neopterin (nM) 7,8 NP (nM) Total neopterin 
(nM) 
42 429.00 - - - 
44 2.00 20.63 12.96 33.59 
50 8342.00 31.18 11.62 42.80 
51 359.00 21.44 7.10 28.54 
53 169.00 13.01 10.87 23.88 
55 8559.00 27.61 22.65 50.25 
58 15543.00 24.72 34.91 59.63 
60 5554.00 37.09 31.38 68.47 
63 12221.00 39.99 17.98 57.97 
66 11536.00 37.40 20.41 57.81 
67 2734.00 26.28 24.25 50.54 
68 8313.00 22.22 24.19 46.41 
69 11186.00 35.29 29.48 64.78 
70 12994.00 33.00 19.58 52.59 
74 5079.00 25.27 11.24 36.51 
76 20453.00 23.10 45.17 68.27 
77 18887.00 17.73 39.15 56.88 
79 9847.00 12.02 11.23 23.25 
83 14754.00 30.23 18.31 48.53 
86 11981.00 30.59 28.92 59.52 
87 10461.00 57.03 24.55 81.58 
89 17043.00 10.11 26.66 36.77 
98 8961.00 30.93 34.83 65.77 
99 9536.00 12.38 46.02 58.40 
100 6206.00 29.14 30.98 60.12 
101 10016.0 15.30 35.37 50.67 
102 2.00 6.18 18.15 24.34 
Table 6.2. General summary of endarterectomy patient’s plasma. Levels of sFlt-1, 
neopterin 7,8 NP and total neopterin measured in patients plasma. Levels expressed as the 
average of duplicate sample testing. Levels of pterin measured in patient 42 were ignored as 


















Patient number sFlt-1 (pg/ml) Neopterin (nM) 7,8 NP (nM) Total neopterin 
(nM) 
42 2.00 - - - 
44 294.00 20.19 8.63 28.82 
50 52.39 14.95 31.81 46.76 
51 9.82 11.16 28.67 39.84 
53 2.00 6.38 22.85 29.23 
55 28.00 13.46 30.77 44.23 
58 294.00 20.41 18.48 38.89 
60 60.39 6.72 24.39 31.11 
63 294.00 14.99 12.06 27.05 
66 6.00 17.14 8.55 25.70 
67 197.00 20.87 12.93 33.80 
68 462.00 25.87 15.79 41.66 
69 769.00 13.18 45.21 58.39 
70 335.00 27.72 16.62 44.34 
74 638.00 9.82 19.27 29.09 
76 710.00 11.55 16.67 28.22 
77 72.73 20.78 36.70 57.49 
79 171.00 16.83 15.01 31.85 
83 548.00 14.41 30.28 44.69 
86 320.00 21.51 16.95 38.47 
87 279.00 14.82 27.75 42.57 
89 874.00 13.12 30.58 43.70 
98 0.0 8.13 30.24 38.37 
99 29.0 13.46 30.77 44.23 
100 0.0 11.72 34.10 45.82 
101 0.0 16.00 31.34 47.34 
102 6.00 17.14 8.55 25.70 
Table 6.3. Age and gender matched healthy control patient plasma. Levels of sFlt-1, 
neopterin 7,8 NP and total neopterin measured in healthy control patients plasma. Levels 
expressed as the mean of duplicate sample testing. Levels of pterin measured in patient 42 were 
ignored as results from the endarterectomy plasma indicated contamination. 
 
 
